EXHIBIT 10.2
STOCK PURCHASE AGREEMENT
by and between
OAM, S.p.A.
and
BION ENVIRONMENTAL TECHNOLOGIES, INC.
dated as of
January 10, 2002
STOCK PURCHASE AGREEMENT
STOCK PURCHASE AGREEMENT, dated as of January 10, 2002 (this
"Agreement"), by and between OAM, S.p.A., an Italian corporation (the "Selling
Stockholder") and Bion Environmental Technologies, Inc., a Colorado
corporation (the "Purchaser").
WHEREAS, the Selling Stockholder is the owner of 3,459,997 shares (the
"Shares") of common stock, par value $.01 per share ("Centerpoint Common
Stock"), of Centerpoint Corporation, a Delaware corporation ("Centerpoint");
WHEREAS, upon the terms and subject to the conditions set forth herein,
the Selling Stockholder desires to sell to the Purchaser, and the Purchaser
desires to purchase from the Selling Stockholder, all of the Shares;
NOW, THEREFORE, in consideration of the foregoing and the respective
representations, warranties, covenants and agreements set forth herein, the
parties hereto agree as follows:
ARTICLE I
PURCHASE AND SALE OF SHARES
Section 1.1 Purchase and Sale of Shares. Upon the terms and subject to
the conditions of this Agreement, at the closing contemplated by this
Agreement (the "Closing"), which is being held simultaneously with the
execution herewith, the Selling Stockholder is selling, transferring,
assigning, conveying and delivering to the Purchaser, and the Purchaser is
purchasing from the Selling Stockholder, the Shares for an aggregate
consideration to consist of:
(a) 1,000,000 (the "Consideration Shares") shares of common stock,
no par value per share, of the Purchaser (the "Purchaser Common Stock"), which
are subject to the restrictions referred to in Section 3.11, and have the
benefit of the registration rights agreement referred to in Section 2.2(a);
(b) a warrant in substantially the form attached hereto as Exhibit
"A", the "Consideration Warrant" and, together with the Consideration Shares,
the "Consideration Securities") to purchase 1,000,000 shares of Purchaser
Common Stock (the "Consideration Warrant Shares");
(c) $3,700,000 in cash;
(d) Assignment of 100% of $4.2 million principal and all accrued
and unpaid interest, represented by that certain note dated June 13, 2001, by
Trident Rowan Group Inc., a Maryland corporation ("TRG"), in favor of
Centerpoint and its transferees and assigns (the "TRG Note");
(e) Assignment of 65% of that certain litigation claim of
Centerpoint against Banca di Intermediazione Mobiliare IMI S.p.A., an Italian
corporation ("IMI"). In connection with such assignment, Selling Stockholder
shall continue to administer any litigation related to, settlement of, or
other resolution of such action and the assigned interest, to the best of its
ability, on behalf of both Selling Stockholder and Centerpoint as
Centerpoint's duly authorized agent. Selling Stockholder acknowledges that
Purchaser has no knowledge whatsoever of the substance, validity or merit of
the claims and makes no warranty or other representation of any kind in
relation thereto;
(f) Assignment of 65% of the Selling Stockholder's right to that
certain escrow account pursuant to the Escrow Agreement by and among the
Selling Stockholder, IMI and Aprillia, S.p.A., an Italian corporation (the
"Aprilia Escrow"). In connection with such assignment, Selling Stockholder
shall continue to administer any litigation related to, settlement of, or
other resolution of such action and the assigned interest, to the best of its
ability, on behalf of both Selling Stockholder and Centerpoint as
Centerpoint's duly authorized agent. Selling Stockholder acknowledges that
Purchaser has no knowledge whatsoever of the substance, validity or merit of
the claims and makes no warranty or other representation of any kind in
relation thereto; and
(g) Release of the Shares from that certain Pledge Agreement dated
June 13, 2001 (the "Pledge Agreement") by and between the Selling Stockholder
and Centerpoint pursuant to the Assignment of Pledge Agreement between
Centerpoint and Purchaser of even date herewith (all such consideration
(a)-(g) above, the "Consideration"). The agreed upon aggregate value of the
Consideration set forth in (d) through (g) above shall be $5,750,000.
Section 1.2 Post-Closing Adjustment. If, prior to the expiration of the
Adjustment Period (as defined below) the Purchaser issues, sells or transfers
any of its equity securities or securities convertible into or exchangeable
for equity securities, at a price which reflects or implies a price per share
of Purchaser Common Stock less than $.75 per share, or amends, by formal
amendment or waiver, the terms of any such outstanding security to reflect or
imply such a price upon the closing of each such issuance, sale or transfer,
the Purchaser shall issue to the Selling Stockholder a number of additional
shares of Purchaser Common Stock computed in accordance with the following
formula:
Y = .75(1,000,000) -1,000,000
--------------
A
Where Y = The number of additional shares of Purchaser Common Stock to
be issued to the Selling Stockholder upon the closing of the
transaction in question.
A = The price per share Purchaser Common Stock reflected or
implied by such transaction.
Provided, however, that notwithstanding anything to the contrary
herein no adjustment shall be made for the issuance by Purchaser
of any equity securities pursuant to the provisions of any of
Purchaser's currently issued and outstanding "J" Warrants.
The "Adjustment Period" shall be a period commencing the day after the date
hereof until such time as the cumulative equity investment in the Purchaser by
third parties unaffiliated with the Selling Stockholder during such period
shall equal $5 million.
ARTICLE II
CLOSING; PAYMENT; DELIVERIES
Section 2.1 The Closing. The Closing is taking place on the date
hereof, at the offices of ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇ LLP, ▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇.
Section 2.2 Deliveries by the Purchaser. At the Closing, the Purchaser
is delivering to the Selling Stockholder:
(a) the consideration contemplated by Section 1.1(a) hereof by
delivery of stock certificates representing the Consideration Shares
registered in the name of the Selling Stockholder and the duly executed
Registration Rights Agreement in the form of Exhibit "B" hereto (the
"Registration Rights Agreement");
(b) the consideration contemplated by Section 1.1(b) hereof by
delivery of the Consideration Warrant;
(c) the consideration contemplated by Section 1.1(c) hereof by
wire transfer in immediately available funds to the account or accounts
specified by the Selling Stockholder in Exhibit C;
(d) the consideration contemplated by Section 1.1(d) hereof by
delivery of the TRG Note accompanied by duly executed instruments of transfer
in substantially the form attached hereto as Exhibit D;
(e) the consideration contemplated by Section 1.1(e) hereof by
delivery of that certain Assignment of Loan Agreement of even date herewith in
substantially the form attached hereto as Exhibit E;
(f) the consideration contemplated by Section 1.1(f) hereof by
delivery of that certain Assignment of Escrow Agreement of even date herewith
in substantially the form attached hereto as Exhibit F;
(g) the consideration contemplated by Section 1.1(g) hereof by
delivery of copies of an effective surrender and termination by Centerpoint of
its rights under the Pledge Agreement in the form of Exhibit G; and
(h) an officer's or director's certificate of the Purchaser
certifying as to (i) resolutions of the Board of Directors of the Purchaser
authorizing the execution, delivery and performance of this Agreement and the
transaction contemplated hereby (ii) a certificate of recent date as to the
good standing of the Purchaser in the jurisdiction of its incorporation (iii)
the Certificate of Incorporation and by-laws of the Purchaser as in effect on
the date of such certificate.
Section 2.3 Deliveries by the Selling Stockholder. At the Closing, the
Selling Stockholder shall deliver to the Purchaser:
(a) a stock certificate or stock certificates representing the
Shares being purchased at the Closing, duly endorsed or accompanied by other
duly executed instruments of transfer;
(b) a countersigned copy of the Registration Rights Agreement;
(c) a copy of all resolutions adopted by the Board of Directors of
the Selling Stockholder authorizing the sale of the Shares to the Purchaser
pursuant to the terms of this Agreement, certified by the Secretary of Selling
Stockholder;
(d) a letter substantially in the form of Exhibit H executed by
the Selling Stockholder and TRG (the "Side Letter").
ARTICLE III
REPRESENTATIONS AND WARRANTIES
OF THE SELLING STOCKHOLDER
The Selling Stockholder represents and warrants to the Purchaser as
follows:
Section 3.1 Organization.
(a) The Selling Stockholder is a corporation duly organized,
validly existing, and in good standing under the laws of Italy, has all
requisite corporate power and authority to own, lease and operate its
properties and to carry on its business as it is now being conducted, and is
qualified or licensed to do business as a foreign corporation and is in good
standing in each jurisdiction in which the nature of the business conducted by
it makes such qualification or licensing necessary, except where the failure
to be so organized, existing and in good standing or to have such power and
authority, or to be so qualified or licensed is not reasonably likely to (x)
have a Material Adverse Effect on the Selling Stockholder; or (y) impair the
ability of the Selling Stockholder to perform its obligations hereunder.
(b) As used in this Agreement, the term "Material Adverse Effect"
shall mean a material adverse effect on the business, assets, results of
operations or financial condition of the Selling Stockholder or the Purchaser,
as the case may be; provided, however, that a Material Adverse Effect shall
not include (a) any change or effect relating or due to general economic or
industry-wide conditions and (b) any change or effect resulting from the
announcement of the parties' intention to execute or execution of this
Agreement or the consummation of the transactions contemplated hereby.
Section 3.2 Authorization; Validity of Agreement.
(a) The Selling Stockholder has the requisite corporate power and
authority to execute and deliver this Agreement, the Side Letter and the
Registration Rights Agreement (collectively the "Selling Stockholder
Transaction Documents") and to consummate the transactions contemplated hereby
and thereby. The execution and delivery by the Selling Stockholder of the
Selling Stockholder Transaction Documents and the consummation of the
transactions contemplated hereby and thereby have been duly authorized by the
Board of Directors of the Selling Stockholder and no other corporate
proceedings on the part of the Selling Stockholder are necessary to authorize
the execution and delivery of the Selling Stockholder Transaction Documents by
the Selling Stockholder and the consummation of the transactions contemplated
hereby and thereby. The Selling Stockholder Transaction Documents have been
duly executed and delivered by the Selling Stockholder and, assuming due
authorization, execution and delivery of the Selling Stockholder Transaction
Documents by the parties hereto other than the Selling Stockholder, are valid
and binding obligations of the Selling Stockholder, enforceable against the
Selling Stockholder in accordance with their terms, except to the extent such
enforcement may be subject to or limited by (i) bankruptcy, insolvency or
other similar laws, now or hereafter in effect, affecting creditors' rights
generally and (ii) the effect of general principles of equity (regardless of
whether enforceability is considered in a proceeding at law or in equity).
Section 3.3 Capitalization. The authorized capital stock of Centerpoint
consists of 20,250,000 shares of Common Stock of which 5,589,092 shares will
be outstanding, excluding shares issued upon exercise or conversion of
options, warrants, convertible debt instruments or other rights outstanding as
of the date hereof, in accordance with their applicable terms, and 4,750,000
shares of Preferred Stock of which no shares will be outstanding, excluding
shares issued upon exercise or conversion of options, warrants, convertible
debt instruments or other rights outstanding as of the date hereof, in
accordance with their applicable terms. Each outstanding share of Centerpoint
Common Stock and Preferred Stock is duly authorized, validly issued, fully
paid and nonassessable, without any personal liability attaching to the
ownership thereof and has not been issued and is not owned or held in
violation of any preemptive rights of stockholders. Except as set forth in
Schedule 3.3, there is no commitment, plan or arrangement to issue, and no
outstanding option, preemptive right, warrant or other right, instrument or
security calling for the issuance of, any share of capital stock of
Centerpoint or any security or other instrument which by its terms is
convertible into, exercisable for or exchangeable for capital stock of
Centerpoint.
Section 3.4 No Violations; Consents and Approvals.
(a) The execution and delivery of the Selling Stockholder
Transaction Documents by the Selling Stockholder and the consummation by the
Selling Stockholder of the transactions contemplated hereby and thereby will
not (i) violate any provision of the certificate of incorporation or bylaws of
the Selling Stockholder, (ii) result in a violation or breach of, or
constitute (with or without due notice or lapse of time or both) a default (or
give rise to any right of termination, amendment, cancellation or
acceleration) under, any of the terms, conditions or provisions of any loan or
credit agreement, note, bond, mortgage, indenture, guarantee, other evidence
of indebtedness, lease, license, contract, agreement or other instrument or
obligation to which the Selling Stockholder is a party or by which any of its
assets may be bound or (iii) violate any order, writ, injunction, decree,
statute, rule or regulation applicable to the Selling Stockholder or any of
its properties or assets; except in the case of clauses (ii) and (iii) for
violations, breaches or defaults which would not reasonably be likely to (x)
have a Material Adverse Effect on the Selling Stockholder; or (y) impair the
ability of the Selling Stockholder to perform its obligations hereunder.
(b) No filing or registration with, notification to, or
authorization, consent or approval of, any foreign, federal, state, local,
municipal, county or other governmental, administrative or regulatory
authority, body, agency, court, tribunal, commission or similar entity
(including any branch, department or official thereof) (a "Governmental
Entity") is required in connection with the execution and delivery of the
Selling Stockholder Transaction Documents by the Selling Stockholder or the
consummation by the Selling Stockholder of the transactions contemplated
hereby and thereby, except for such consents, approvals, orders,
authorizations, notifications, registrations, declarations and filings the
failure of which to be obtained or made which would not reasonably be likely
to (x) have a Material Adverse Effect on the Selling Stockholder; or (y)
impair the ability of the Selling Stockholder to perform its obligations
hereunder.
Section 3.5 Ownership and Possession of Shares.
(a) The Shares and the certificates representing the Shares are
now owned by the Selling Stockholder, or by a nominee or custodian for the
sole and exclusive benefit of the Selling Stockholder and, upon delivery to
Purchaser of the surrender and termination by Centerpoint of its rights under
the Pledge Agreement as set forth in Section 2.2(g), will be free and clear of
all Encumbrances whatsoever, except for any Encumbrances created by this
Agreement and Encumbrances arising under the Securities Act of 1933, as
amended (the "Securities Act") or state securities laws.
(b) As used in this Agreement, the term "Encumbrances" shall mean
any and all liens, charges, security interests, options, claims, mortgages,
pledges, hypothecations, proxies, voting trusts or agreements, obligations,
understandings or arrangements or other restrictions on title or transfer of
any nature whatsoever.
Section 3.6 Good Title Conveyed. The stock certificates, stock powers,
endorsements, assignments, and other instruments being executed and delivered
by the Selling Stockholder to the Purchaser at the Closing will be valid and
binding obligations of the Selling Stockholder, enforceable in accordance with
their respective terms, and will effectively vest in the Purchaser good, valid
and marketable title to all the Shares pursuant to and as contemplated by this
Agreement free and clear of all Encumbrances, except restrictions on transfer
imposed by the Securities Act of 1933, as amended (the "Securities Act"), and
state securities laws.
Section 3.7 Centerpoint SEC Reports and Financial Statements.
(a) Except as set forth on Schedule 3.7(a), Centerpoint has filed
all forms, reports and documents required to be filed by it with the SEC since
June 30, 1998 (together, the "Centerpoint SEC Reports"). The forms, reports
and documents filed by Centerpoint from December 1, 1998 through March 31,
2000, and Note 21 (the "Subsequent Event Note") to the financial statements
included in TRG's Form 10-K for the fiscal year ended December 31, 1999 (i)
were prepared in accordance with the requirements of the Securities Act or the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), as the case
may be, and (ii) did not at the time they were filed contain any untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary in order to make the statements made therein, in
the light of the circumstances under which they were made, not misleading.
(b) Each of the consolidated financial statements (including, in
each case, any notes thereto) contained in the Centerpoint SEC Reports (the
"Centerpoint Financial Statements"), as they would need to be adjusted to take
into account the events reflected in the Subsequent Event Note (i) was
prepared from the books of account and other financial records of Centerpoint
and its Subsidiaries (as defined herein), (ii) was prepared in accordance with
United States generally accepted accounting principles ("U.S. GAAP") applied
on a consistent basis throughout the periods indicated (except as may be
indicated in the notes thereto) and (iii) presented fairly the consolidated
financial position of Centerpoint and its consolidated Subsidiaries as at the
respective dates thereof and the results of their operations and their cash
flows for the respective periods indicated therein except as otherwise noted
therein (subject, in the case of unaudited statements, to the omission of
footnotes and normal and recurring year-end adjustments which were not and are
not expected, individually or in the aggregate, to have a Material Adverse
Effect on Centerpoint).
(c) The Selling Stockholder has heretofore furnished to the
Purchaser complete and correct copies of (i) all agreements, documents and
other instruments not yet filed by Centerpoint with the SEC but that are
currently in effect and that Centerpoint expects to file with the SEC after
the date of this Agreement and (ii) all amendments and modifications that have
not been filed by Centerpoint with the SEC to all agreements, documents and
other instruments that previously had been filed by Centerpoint with the SEC
and are currently in effect.
(d) Except as set forth in Schedule 3.7(d), Centerpoint has no
liabilities or other obligations of a nature that would be required to be set
disclosed on a balance sheet of Centerpoint or the footnotes thereto prepared
in accordance with GAAP, other than liabilities and other obligations which,
individually or in the aggregate, could not reasonably be expected to have a
Material Adverse Effect on Centerpoint.
Section 3.8 Bank Statements. The bank statement of Centerpoint for the
month ended December 31, 2001, in the form previously delivered to the
Purchaser, fairly and accurately reflects the accounts of Centerpoint as of
such date.
Section 3.9 Brokers. Except for Investec Ernst & Co. ("Investec") and
▇▇▇▇▇▇ ▇▇▇▇▇▇▇ & Company, Inc., no broker, finder or investment banker is
entitled to any brokerage, finder's or other fee or commission in connection
with the transactions contemplated by this Agreement or based upon
arrangements made by or on behalf of the Selling Stockholder or Centerpoint.
Centerpoint is solely responsible for the fees and expenses of Investec.
Section 3.10 Investment Representations. The Selling Stockholder is
acquiring the Consideration Securities for the Selling Stockholder's own
account for investment and not with a view to the sale or distribution thereof
or the granting of any participation therein, and has no present intention of
distributing or selling to others any of such interest or granting any
participation therein.
(b) The Selling Stockholder has been advised by the Purchaser that the
Consideration Securities have not yet been registered under the Act, that the
Consideration Securities will be issued on the basis of the statutory
exemption provided by Section 4(2) of the Securities Act, or Regulation D
promulgated thereunder, or both, relating to transactions by an issuer not
involving any public offering and under similar exemptions under certain state
securities laws, that this transaction has not been reviewed by, passed on or
submitted to any federal or state agency or self-regulatory organization where
an exemption is being relied upon, and that the Purchaser's reliance thereon
is based in part upon the representations made by the Selling Stockholder in
this Agreement. The Selling Stockholder acknowledges that the Selling
Stockholder is otherwise familiar with, the nature of the restriction imposed
by the Act and the rules and regulations thereunder on the transfer of the
Consideration Securities. In particular, the Selling Stockholder agrees that
no sale, assignment or transfer of the Consideration Securities shall be valid
or effective, and the Purchaser shall not be required to give any effect to
such a sale, assignment or transfer, unless (i) the sale, assignment or
transfer of the Consideration Securities is registered under the Act, it being
understood that the Consideration Securities are not yet registered for
re-sale although the Purchaser has agreed to so register the Consideration
Securities as provided in the Registration Rights Agreement, or (ii) the
Consideration Securities are sold, assigned or transferred in accordance with
all the requirements and limitations of Rule 144 under the Securities Act, it
being understood that Rule 144 is not available at the present time for the
sale of the Consideration Securities, or (iii) such sale, assignment or
transfer of the Consideration Securities is otherwise exempt from registration
under the Securities Act. The Selling Stockholder further understands that
absent registration under the Securities Act, an opinion of counsel and other
documents may be required to transfer the Consideration Securities. The
Selling Stockholder acknowledges that the Consideration Securities shall be
subject to a stop transfer order and the certificates evidencing any
Consideration Securities shall bear the following or a substantially similar
legend or such other legend as may appear on the forms of the Consideration
Securities and such other legends as may be required by state blue sky laws
for so long as the Consideration Securities remain unregistered under the Act:
"The securities represented by this certificate have not been registered
under the Securities Act of 1933, as amended (the "Act"), or any state
securities laws and neither such securities nor any interest therein may
be offered, sold, pledged, assigned or otherwise transferred unless (1)
a registration statement with respect thereto is effective under the Act
and any applicable state securities laws or (2) the Purchaser receives
an opinion of counsel to the holder of such securities, which counsel
and opinion are reasonably satisfactory to the Purchaser, that such
securities may be offered, sold, pledged, assigned or transferred in the
manner contemplated without an effective registration statement under
the Act or applicable state securities laws."
Section 3.11 No Other Representations or Warranties. Except for the
representations and warranties contained in this Article III, neither the
Selling Stockholder nor any other Person (as defined herein) makes any other
express or implied representation or warranty on behalf of the Selling
Stockholder or any of its affiliates in connection with the transactions
contemplated hereby.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES
OF THE PURCHASER
The Purchaser represents and warrants to the Selling Stockholder as
follows:
Section 4.1 Organization. The Purchaser is a corporation duly
organized, validly existing and in good standing under the laws of the State
of Colorado, has all requisite corporate power and authority to own, lease and
operate its properties and to carry on its business as now being conducted,
and is qualified or licensed to do business as a foreign corporation and is in
good standing in each jurisdiction in which the nature of the business
conducted by it makes such qualification or licensing necessary, except where
the failure to be so organized, existing and in good standing or to have such
power and authority, or to be so qualified or licensed is not reasonably
likely to (x) have a Material Adverse Effect on the Purchaser; or (y) impair
the ability of the Purchaser to perform its obligations hereunder.
Section 4.2 Capitalization and Indebtedness. The authorized capital
stock of Purchaser consists of 100,000,000 shares of Purchaser's Common Stock
of which 13,481,930 are issued and outstanding as of the date hereof without
giving effect to the issuance of shares to Selling Shareholder and Centerpoint
pursuant to the transactions contemplated hereby or the automatic conversion
of any of Purchaser's convertible debt securities as a result of the
transaction contemplated hereby. In accordance with the terms of the
convertible securities of the Purchaser set forth on Schedule 4.2 hereof, the
convertible securities will by their terms be converted into not more than
19,050,000 shares of Purchaser's Common Stock upon the consummation of the
transactions contemplated by this Agreement (the "Conversion of Indebtedness")
if conversion occurs on or before January 15, 2002. Each outstanding share of
Purchaser's Common Stock is duly authorized, validly issued, fully paid and
nonassessable, without any personal liability attaching to the ownership
thereof and has not been issued and is not owned or held in violation of any
preemptive rights of stockholders. Except as set forth on Schedule 4.2, there
is no commitment, plan or arrangement to issue, and no outstanding option,
preemptive right, warrant or other right, instrument or security calling for
the issuance of any share of capital stock of the Purchaser or any security or
other instrument which by its terms is convertible into, exercisable for or
exchangeable for capital stock of the Purchaser. As of the date hereof the
Purchaser is not in default with respect to any Indebtedness and the
consummation of the transactions contemplated by this Agreement and the
Centerpoint Stock Subscription Agreement will not result in any such default.
Immediately following the consummation of the transactions contemplated by
this Agreement and the Conversion of Indebtedness if conversion occurs on or
before January 15, 2002, the total outstanding indebtedness of the Purchaser
shall not be greater than $950,000, and indebtedness other than subordinated
indebtedness shall not be greater than $950,000.
Section 4.3 Authorization; Validity of Agreement. The Purchaser has the
requisite corporate power and authority to execute and deliver this Agreement
and the documents and agreements attached hereto as exhibits to be executed
and delivered by Purchaser (such documents and exhibits, the "Purchaser
Transaction Documents"). The execution and delivery by the Purchaser of this
Agreement and the Purchaser Transaction Documents and the consummation of the
transactions contemplated hereby and thereby have been duly authorized by the
Board of Directors of the Purchaser, and no other corporate proceedings on the
part of the Purchaser are necessary to authorize the execution and delivery of
this Agreement and the Purchaser Transaction Documents by the Purchaser and
the consummation of the transactions contemplated hereby and thereby. This
Agreement and the Purchaser Transaction Documents have been duly executed and
delivered by the Purchaser and, assuming due authorization, execution and
delivery of this Agreement and the Purchaser Transaction Documents by the
parties thereto other than the Purchaser, are valid and binding obligations of
the Purchaser, enforceable against the Purchaser in accordance with their
respective terms, except to the extent such enforcement may be subject to or
limited by (i) bankruptcy, insolvency or other similar laws, now or hereafter
in effect, affecting creditors' rights generally and (ii) the effect of
general principles of equity (regardless of whether enforceability is
considered in a proceeding at law or in equity).
Section 4.4 No Violations; Consents and Approvals.
(a) The execution and delivery of this Agreement and the Purchaser
Transaction Documents by the Purchaser and the consummation by the Purchaser
of the transactions contemplated hereby and thereby will not (i) violate any
provision of the certificate of incorporation or bylaws of the Purchaser, (ii)
result in a violation or breach of, or constitute (with or without due notice
or lapse of time or both) a default (or give rise to any right of termination,
amendment, cancellation or acceleration) under, any of the terms, conditions
or provisions of any material note, bond, mortgage, indenture, guarantee,
other evidence of indebtedness, license, lease, contract, agreement or other
instrument or obligation to which the Purchaser or any of its Subsidiaries is
a party or by which any of them or any of their assets may be bound or (iii)
violate any order, writ, injunction, decree, statute, rule or regulation
applicable to the Purchaser, any of its Subsidiaries or any of their
properties or assets, except in the case of clauses (ii) and (iii) for
violations, breaches or defaults which would not reasonably be likely to (x)
have a Material Adverse Effect on the Purchaser; or (y) impair the ability of
the Purchaser to perform its obligations hereunder.
(b) No filing or registration with, notification to, or
authorization, consent or approval of, any Governmental Entity is required in
connection with the execution and delivery of this Agreement or the Purchaser
Transaction Documents by the Purchaser or the consummation by the Purchaser of
the transactions contemplated hereby and thereby, except such consents,
approvals, orders, authorizations, notifications, registrations, declarations
and filings the failure of which to be obtained or made would not reasonably
be likely to (x) have a Material Adverse Effect on the Purchaser; or (y)
impair the ability of the Purchaser to perform its obligations hereunder.
Section 4.5 Issuance of Consideration Shares at the Closing. The
Consideration Shares, being issued at the Closing are, and the Consideration
Warrant Shares will be, when issued, validly issued, fully paid and
nonassessable, and the issuance of such shares is not subject to preemptive or
subscription rights.
Section 4.6 Good Title Conveyed. The stock certificates, stock powers,
endorsements, assignments and other instruments being executed and delivered
by the Purchaser to the Selling Stockholder at the Closing will be valid and
binding obligations of the Purchaser, enforceable in accordance with their
respective terms, and will effectively vest in the Selling Stockholder good,
valid and marketable title to all the Consideration to be transferred to the
Selling Stockholder pursuant to and as contemplated by this Agreement free and
clear of all Encumbrances, except restrictions on transfer imposed by the
Securities Act and state securities laws.
Section 4.7 Purchaser SEC Reports and Financial Statements.
(a) The Purchaser has filed all forms, reports and documents
required to be filed by it with the SEC since June 30, 1998 (collectively, the
"Purchaser SEC Reports"). The Purchaser SEC Reports (i) were prepared in
accordance with the requirements of the Securities Act or the Exchange Act, as
the case may be, and (ii) did not at the time they were filed contain any
untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not
misleading.
(b) Each of the consolidated financial statements (including, in
each case, any notes thereto) contained in the Purchaser SEC Reports (the
"Purchaser Financial Statements") (i) was prepared from the books of account
and other financial records of the Purchaser and its Subsidiaries, (ii) was
prepared in accordance with U.S. GAAP applied on a consistent basis throughout
the periods indicated (except as may be indicated in the notes thereto) and
(iii) presented fairly the consolidated financial position of the Purchaser
and its consolidated Subsidiaries as at the respective dates thereof and the
results of their operations and their cash flows for the respective periods
indicated therein except as otherwise noted therein (subject, in the case of
unaudited statements, to the omission of footnotes and normal and recurring
year-end adjustments which were not and are not expected, individually or in
the aggregate, to have a Material Adverse Effect on the Purchaser).
(c) The Purchaser has heretofore furnished to the Selling
Stockholder complete and correct copies of (i) all agreements, documents and
other instruments not yet filed by the Purchaser with the SEC but that are
currently in effect and that the Purchaser expects to file with the SEC after
the date of this Agreement and (ii) all amendments and modifications that have
not been filed by the Purchaser with the SEC to all agreements, documents and
other instruments that previously had been filed by the Purchaser with the SEC
and are currently in effect.
(d) No Undisclosed Liabilities. Except as disclosed in the
Purchaser SEC Reports filed prior to the date hereof and an additional amount
of approximately $350,000 which has been advanced by affiliates of Purchaser
since the date of its most recent Quarterly Report on Form 10-QSB, since
December 31, 2000, Purchaser has not incurred any liabilities that are of a
nature that would be required to be disclosed on its balance sheet or the
footnotes thereto prepared in conformity with GAAP, other than (i) liabilities
incurred in the ordinary course of business or (ii) liabilities that,
individually or in the aggregate, would not reasonably be expected to have a
Material Adverse Effect on the Purchaser.
Section 4.8 Brokers. No broker, finder or investment banker is
entitled to any brokerage, finder's or other fee or commission in connection
with the transactions contemplated by this Agreement based upon arrangements
made by or on behalf of the Purchaser.
Section 4.9 No Resale. The Purchaser is acquiring the Shares for
the Purchaser's own account for investment and not with a view to the sale or
distribution thereof or the granting of any participation therein, and has no
present intention of distributing or selling to others any of such interest or
granting any participation therein.
(b) The Purchaser has been advised by the Selling Stockholder that
the Shares are not registered and are being transferred hereunder on the basis
of the statutory exemption under the Securities Act and under similar
exemptions under certain state securities laws, that this transaction has not
been reviewed by, passed on or submitted to any federal or state agency or
self-regulatory organization where an exemption is being relied upon, and that
the Selling Stockholder's reliance thereon is based in part upon the
representations made by the Purchaser in this Agreement. The Purchaser
acknowledges that the Purchaser is otherwise familiar with the nature of the
restriction imposed by the Act and the rules and regulations thereunder on the
transfer of the Shares, by the legend reflected on the share certificate being
conveyed to the Purchaser at Closing and by the other restrictions that may
have been placed thereon by Centerpoint.
Section 4.10 No Other Representations or Warranties. Except for
the representations and warranties contained in this Article IV, neither the
Purchaser nor any other Person makes any other express or implied
representation or warranty on behalf of the Purchaser or any of its
affiliates.
ARTICLE V
REGISTRATION RIGHTS
The parties acknowledge that the Selling Stockholder is accepting the
Consideration Shares and the Consideration Warrants in reliance on covenants
made by the Purchaser in the Registration Rights Agreement. Selling
Stockholder agrees that during the term of the Registration rights Agreement,
neither the Selling Stockholder nor any of its affiliates, agents, successors
or assigns shall engage in any short sales of the Purchaser's Common Stock,
and that in the event that any such person engages in short sales of the
Purchaser's Common Stock against the future delivery of any pro rata share of
Purchaser's securities pursuant to a registration statement or otherwise, the
Purchaser shall have no obligation to deliver such pro rata share of such
securities to any such person.
ARTICLE VI
MISCELLANEOUS
Section 6.1 Public Announcements. The Purchaser and the Selling
Stockholder shall, and shall cause their affiliates to, consult promptly with
each other prior to issuing any press release, making any required filing or
otherwise making any public statement with respect to this Agreement and the
transactions contemplated hereby, provide to the other party within a
reasonable timeframe for review a copy of any such press release or statement,
and shall not issue any such press release, public filing or make any such
public statement prior to such consultation and a reasonable opportunity for
review and comment, the duration of which is specified at the time of review
and shall make reasonable efforts to accommodate the comments of the other
party, unless otherwise required by applicable law or any listing agreement
with a securities exchange.
Section 6.2 Fees and Expenses. All costs and expenses incurred by a
party in connection with this Agreement and the consummation of the
transactions contemplated hereby shall be paid by the party incurring such
costs or expenses.
Section 6.3 Non-Survival of Representations and Warranties. Other than
the representations and warranties set forth in Sections 3.8, 4.2 and 4.6,
which shall survive in perpetuity, the representations and warranties made in
this Agreement shall survive only until the second anniversary of the date
hereof.
Section 6.4 Amendment; Waiver. This Agreement may be amended, modified
or supplemented by the parties hereto, at any time. This Agreement may not be
amended except by an instrument in writing signed on behalf of each of the
parties hereto.
Section 6.5 Notices. All notices and other communications hereunder
shall be in writing and shall be deemed given upon (a) transmitter's
confirmation of a receipt of a facsimile transmission, (b) confirmed delivery
by a standard overnight carrier or when delivered by hand or (c) the
expiration of five business days after the day when mailed in the United
States or Italy by certified or registered mail, postage prepaid, addressed at
the following addresses (or at such other address for a party as shall be
specified by like notice):
(a) If to the Selling Stockholder, to:
OAM S.p.A.
▇▇▇ ▇▇▇▇▇ ▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇
Facsimile: 011-39-02-72000457
Attention: Board of Directors
with a copy to:
▇▇▇▇ ▇▇▇▇▇▇
FDG Associates
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
(b) If to the Purchaser, to:
Bion Environmental Technologies, Inc.
▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
Attention: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
with a copy to:
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇., ▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Section 6.6 Certain Definitions. As used in this Agreement:
(a) The term "affiliate", as applied to any person, shall mean any
other person directly or indirectly controlling, controlled by, or under
common control with, that person.
(b) The term "Person" or "person" shall include individuals,
corporations, partnerships, trusts, other entities and groups (which term
shall include a "group" as such term is defined in Section 13(d)(3) of the
Exchange Act).
(c) The term "Subsidiary" or "Subsidiaries", with respect to any
person, means any corporation, partnership, joint venture or other legal
entity of which such person (either alone or through or together with any
other subsidiary), owns, directly or indirectly, stock or other equity
interests the holders of which are generally entitled to more than 50% of the
vote for the election of the board of directors or other governing body of
such corporation or other legal entity.
Section 6.7 Interpretation. When a reference is made in this Agreement
to a section, article, paragraph, clause, annex or exhibit, such reference
shall be to a reference to this Agreement unless otherwise clearly indicated
to the contrary. The descriptive article and section headings herein are
intended for convenience of reference only and are not intended to be a part
of or to affect the meaning or interpretation of this Agreement. Whenever the
words "include," "includes" or "including" are used in this Agreement they
shall be deemed to be followed by the words "without limitation." The words
"hereof," "herein" and "herewith" and words of similar import shall, unless
otherwise stated, be construed to refer to this Agreement as a whole and not
to any particular provision of this Agreement. The meaning assigned to each
term used in this Agreement shall be equally applicable to both the singular
and the plural forms of such term, and words denoting either gender shall
include both genders. Where a word or phrase is defined herein, each of its
other grammatical forms shall have a corresponding meaning.
Section 6.8 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original but all of which shall
be considered one and the same agreement.
Section 6.9 Entire Agreement. This Agreement constitutes the entire
agreement, and supersedes all prior agreements and understandings (written and
oral), between the parties with respect to the subject matter hereof.
Section 6.10 Severability. If any term, provision, covenant or
restriction of this Agreement is held by a court of competent jurisdiction or
other authority to be invalid, void, unenforceable or against its regulatory
policy, the remainder of the terms, provisions, covenants and restrictions of
this Agreement shall remain in full force and effect and shall in no way be
affected, impaired or invalidated.
Section 6.11 Specific Performance. Irreparable damage would occur in
the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached; accordingly,
the parties shall be entitled to an injunction or injunctions to prevent
breaches of this Agreement and to enforce specifically the terms and
provisions hereof in any court of the United States or any state having
jurisdiction, this being in addition to any other remedy to which they are
entitled at law or in equity.
Section 6.12 Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT GIVING
EFFECT TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF.
Section 6.13 Submission to Jurisdiction. Each of the Selling Stockholder
and the Purchaser hereby irrevocably submits in any action, suit or proceeding
arising out of this Agreement or any of the transactions contemplated hereby
to the exclusive jurisdiction of the United States District Court for the
Southern District of New York and the jurisdiction of any court of the State
of New York located in the City of New York. The parties hereto waive any and
all objections to the laying of venue of any such litigation in such
jurisdiction and agree not to plead or claim in any such litigation that such
litigation has been brought in an inconvenient forum.
Section 6.14 Waiver of Jury Trial. Each party acknowledges and agrees
that any controversy which may arise under this Agreement is likely to involve
complicated and difficult issues, and therefore each such party hereby
irrevocably and unconditionally waives any right such party may have to a
trial by jury in respect of any litigation directly or indirectly arising out
of or relating to this Agreement, or the transactions contemplated by this
Agreement. Each party certifies and acknowledges that (i) no representative,
agent or attorney of any other party has represented, expressly or otherwise,
that such other party would not, in the event of litigation, seek to enforce
the foregoing waiver, (ii) each such party understands and has considered the
implications of this waiver, (iii) each such party makes this waiver
voluntarily and (iv) each such party has been induced to enter into this
Agreement by, among other things, the mutual waivers and certifications in
this Section 6.14.
Section 6.15 Assignment. Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned by either party hereto
(whether by operation of law or otherwise) without the prior written consent
of the other party. Subject to the preceding sentence, this Agreement will be
binding upon, inure to the benefit of and be enforceable by, the parties and
their respective successors and assigns and are not intended to confer upon
any Person other than the parties hereto any rights or remedies hereunder.
Section 6.16 Legal Representation of Investec. The parties hereto
acknowledge that ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇ LLP ("▇▇▇▇▇▇ ▇▇▇▇▇") was
retained by Investec to represent Investec in connection with the transactions
contemplated hereby and that, notwithstanding the fact that from time to time
▇▇▇▇▇▇ ▇▇▇▇▇ has represented various affiliates of the Selling Stockholder in
connection with specific transactions, the parties understand ▇▇▇▇▇▇ Levin's
preparation of this Agreement and the documents contemplated hereby was solely
at the request of and in its role as counsel to Investec Neither party hereto
is relying on ▇▇▇▇▇▇ ▇▇▇▇▇ for representation or advice in connection with
this Agreement or with the transactions contemplated hereby and without a
written agreement to the contrary, ▇▇▇▇▇▇ ▇▇▇▇▇ shall owe no duties to any
party hereto.
[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
IN WITNESS WHEREOF, the undersigned have caused this Agreement to be
signed by their respective officers thereunto duly authorized as of the date
first written above.
OAM S.p.A.
By:/s/ ▇▇▇▇ ▇▇▇▇▇▇
Name:
Title:
BION ENVIRONMENTAL TECHNOLOGIES, INC.
By:/s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: CEO
SCHEDULE 3.3 TO
STOCK PURCHASE AGREEMENT
The attached table includes all options and warrants of Centerpoint
outstanding as of December 31, 1999, other than warrants to purchase 100,000
shares of Common Stock of Centerpoint issued to OAM in July 1999 which were
exercised in June 2000 and warrants to purchase 25,000 shares of Common Stock
issued to ▇▇▇▇▇▇ ▇▇▇▇▇▇, as reflected in Centerpoint's 12/31/99 Form 10-K.
The expiration dates (or status) of options and warrants included in the
table are as follows:
Item No. Expiration Date (or Status)
1 March 31, 2002
2 March 31, 2002
3 March 31, 2002
4 Exercised in March 1999
5 Exercised in March 1999
6 March 31, 2002
7 March 31, 2002
8 August 22, 2002
9 August 22, 2002
10 August 22, 2002
11 August 22, 2002
12 August 22, 2002
13 August 22, 2002
14 August 22, 2002
15 Expired
16 July 1, 2003
17 Cancelled
18 March 2009
19 March 2009
20 February 2010
21 Exchanged for Series B Preferred Stock
The only options or warrants issued since December 31, 1999 are options
issued to non-employee directors under Centerpoint's 1995 Directors Plan which
provides for the issuance of 12,500 ten-year options to each non-employee
Director on January 4 of each year at the reported closing price of the stock
on the January 2 preceding such issuance.
EXHIBIT A
THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY
STATE SECURITIES LAWS AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY
BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A
REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS, OR (2) THE COMPANY RECEIVES AN OPINION OF
COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH OPINION IS REASONABLY
SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD,
PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES
LAWS.
BION ENVIRONMENTAL TECHNOLOGIES, INC.
Warrant for the Purchase of Shares of Common Stock,
no par value per share
THIS WARRANT BECOMES EXERCISABLE ON JANUARY 10, 2002
AND EXPIRES ON JANUARY 10, 2007
1,000,000 Shares
----------------
THIS CERTIFIES that, for value received, OAM, S.p.A., an Italian
corporation, with an address at ▇▇▇ ▇▇▇▇▇ ▇, ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ("OAM", and,
with any transferee, the "Holder"), is entitled to subscribe for and purchase
from Bion Environmental Technologies, Inc., a Colorado corporation (the
"Company"), upon the terms and conditions set forth herein, at any time or
from time to time after January 10, 2002 and before 5:00 P.M. on January 10,
2007, New York time (the "Exercise Period"), 1,000,000 shares of the Company's
Common Stock, no par value per share (the "Common Stock"), at an initial
Exercise Price of $0.90 per share. For the purposes of this Warrant, the term
"Transaction Price" shall mean the price at which the Company issues shares to
Centerpoint Corporation, a Delaware corporation ("Centerpoint"), pursuant to
that certain Subscription Agreement dated January 10, 2002 between the Company
and Centerpoint, as such price may be adjusted from time to time pursuant to
the terms of such Subscription Agreement.
This Warrant is issued to the Holder as partial consideration in
connection with the Company's purchase from OAM of 3,460,017 shares of the
common stock of Centerpoint pursuant to that certain Stock Purchase Agreement
between OAM and the Company dated December 31, 2001 (the "Stock Purchase
Agreement"). As used herein the term "this Warrant" shall mean and include
this Warrant and any Warrant or Warrants hereafter issued as a consequence of
the exercise or transfer of this Warrant in whole or in part.
The number of shares of Common Stock issuable upon exercise of this
Warrant (the "Warrant Shares") and the Exercise Price may be adjusted from
time to time as hereinafter set forth.
1. This Warrant may be exercised during the Exercise Period, as to the
whole or any lesser number of whole Warrant Shares, by the surrender of this
Warrant (with the election at the end hereof duly executed) to the Company at
its office at ▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ 10022,
Attention: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, or at such other place as is designated in writing
by the Company.
(a) Subject to Section 1(b) hereof, such executed election must be
accompanied by payment in an amount equal to the Exercise Price multiplied by
the number of Warrant Shares for which this Warrant is being exercised. Such
payment may be made by certified or bank cashier's check payable to the order
of the Company, or as otherwise provided in Section 1(b) hereof.
(b) In lieu of exercising this Warrant via cash payment, the
Holder may effect a cashless exercise and receive Warrant Shares equal to the
value of this Warrant (or the portion thereof being canceled) by means of a
net issuance exercise, in which event the Company shall issue to the Holder a
number of Warrant Shares computed using the following formula:
X = Y (A - B)
---------
A
Where X = the number of Warrant Shares to be issued to the
Holder.
Y = the number of Warrant Shares purchasable under this
Warrant or, if only a portion of the Warrant is being
exercised, the Warrant Shares purchasable under the
portion of the Warrant being exercised (at the date
of
such calculation).
A = the Current Market Price (as defined below) of one
share of Common Stock (at the date of such
calculation).
B = the Exercise Price (as adjusted to the date of such
calculation).
If the above calculation results in a negative number, then no
Warrant Shares shall be issued or issuable upon conversion of this Warrant
pursuant to this Section 1(b), and the Warrant shall not be deemed to have
been exercised, notwithstanding the delivery of the notice of election.
(c) The "Current Market Price" of one share of Common Stock shall
mean the average closing price of the Common Stock for the five (5) trading
days prior to the date of determination (the "Average Closing Price"), as
reported by the O.T.C. Bulletin Board (the "O.T.C. Bulleting Board") or the
National Association of Securities Dealers Automated Quotation System
("NASDAQ"), or if the stock is not traded on either the O.T.C. Bulletin Board
or NASDAQ, the Average Closing Price reported by any other over-the-counter
market; provided, however, that if the Common Stock is listed on an exchange,
the Current Market Price shall be the Average Closing Price on such exchange
for the five (5) trading days prior to the date of determination. If the
Common Stock is/was not traded during the five (5) trading days prior to the
date of determination, then the closing price for the last publicly traded day
shall be deemed to be the closing price for any and all (if applicable) days
during such five (5) trading day period.
2. Upon each exercise of the Holder's rights to purchase Warrant Shares,
the Holder shall be deemed to be the holder of record of the Warrant Shares
issuable upon such exercise, notwithstanding that the transfer books of the
Company shall then be closed or certificates representing such Warrant Shares
shall not then have been actually delivered to the Holder. As soon as
practicable after each such exercise of this Warrant, the Company shall issue
and deliver to the Holder a certificate or certificates for the Warrant Shares
issuable upon such exercise, registered in the name of the Holder or its
designee. If this Warrant should be exercised in part only, the Company
shall, upon surrender of this Warrant for cancellation, execute and deliver a
new Warrant evidencing the right of the Holder to purchase the balance of the
Warrant Shares (or portions thereof) subject to purchase hereunder.
3. (a) Any Warrants issued upon the transfer or exercise in part of
this Warrant shall be numbered and shall be registered in a Warrant Register
as they are issued. The Company shall be entitled to treat the registered
holder of any Warrant on the Warrant Register as the owner in fact thereof for
all purposes and shall not be bound to recognize any equitable or other claim
to or interest in such Warrant on the part of any other person. This Warrant
shall be transferable only on the books of the Company upon delivery thereof
duly endorsed by the Holder or by his duly authorized attorney or
representative, or accompanied by proper evidence of succession, assignment,
or authority to transfer. In all cases of transfer by an attorney, executor,
administrator, guardian, or other legal representative, duly authenticated
evidence of his or its authority shall be produced. Upon any transfer or
partial exercise, the Company shall deliver a new Warrant or Warrants to the
person entitled thereto. This Warrant may be exchanged, at the option of the
Holder thereof, for another Warrant, or other Warrants of different
denominations, of like tenor and representing in the aggregate the right to
purchase a like number of Warrant Shares (or portions thereof), upon surrender
to the Company or its duly authorized agent. Notwithstanding the foregoing,
the Company shall have no obligation to cause Warrants to be transferred on
its books to any person if, in the opinion of counsel to the Company, such
transfer does not comply with the provisions of the Securities Act of 1933, as
amended (the "Act"), and the rules and regulations promulgated thereunder.
(b) The Holder acknowledges that it has been advised by the
Company that neither this Warrant nor the Warrant Shares have been registered
under the Act, that this Warrant is being or has been issued and the Warrant
Shares may be issued on the basis of the statutory exemption provided by
Section 4(2) of the Act or Regulation D promulgated thereunder, or both,
relating to transactions by an issuer not involving any public offering. The
Holder acknowledges that it has been informed by the Company of, or is
otherwise familiar with, the nature of the limitations imposed by the Act and
the rules and regulations thereunder on the transfer of securities. In
particular, the Holder agrees that no sale, assignment or transfer of this
Warrant or the Warrant Shares issuable upon exercise hereof shall be valid or
effective, and the Company shall not be required to give any effect to any
such sale, assignment or transfer, unless (i) the sale, assignment or transfer
of this Warrant or such Warrant Shares is registered under the Act, it being
understood that neither this Warrant nor such Warrant Shares are currently
registered for sale and that the Company has no obligation or intention to so
register this Warrant or such Warrant Shares except as specifically provided
herein or in that certain Registration Rights Agreement between the Company
and the Holder dated the date hereof (the "Registration Rights Agreement"), or
(ii) this Warrant or such Warrant Shares are sold, assigned or transferred in
accordance with all the requirements and limitations of Rule 144 promulgated
under the Act, it being understood that Rule 144 is not available at the time
of the original issuance of this Warrant for the sale of this Warrant or such
Warrant Shares and that there can be no assurance that Rule 144 sales will be
available at any subsequent time, or (iii) such sale, assignment, or transfer
is otherwise exempt from registration under the Act.
4. The Company shall at all times reserve and keep available out of its
authorized and unissued Common Stock, solely for the purpose of providing for
the exercise of the rights to purchase all Warrant Shares granted pursuant to
this Warrant, such number of shares of Common Stock as shall, from time to
time, be sufficient therefor. The Company covenants that all shares of Common
Stock are validly authorized and, if and when this Warrant is exercised in
whole or in part, the shares of Common Stock issued upon such exercise, upon
receipt by the Company of the full Exercise Price therefor as determined
pursuant to Section 1(a) or 1(b), as the case may be, shall be validly issued,
fully paid, nonassessable, without any personal liability attaching to the
ownership thereof, and will not be issued in violation of any preemptive or
other rights of stockholders.
5. (a) In case the Company shall at any time after the date this
Warrant is first issued (i) declare a dividend on the outstanding Common Stock
of the Company payable in shares of its Common Stock, (ii) subdivide the
outstanding Common Stock, or (iii) combine the outstanding Common Stock into a
smaller number of shares, then, in each case, the Exercise Price, and the
number of Warrant Shares issuable upon exercise of this Warrant, in effect at
the time of the record date for such dividend or of the effective date of such
subdivision, or combination, shall be proportionately adjusted so that the
Holder after such time shall be entitled to receive the aggregate number and
kind of shares for such consideration which, if such Warrant had been
exercised immediately prior to such time at the Exercise Price, such holder
would have owned upon such exercise and been entitled to receive by virtue of
such dividend, subdivision, or combination.
(b) Subject to the limitations set forth in this Section 5(b)
below, in case the Company shall issue or fix a record date for the issuance
to all holders of Common Stock of rights, options, or warrants to subscribe
for or purchase Common Stock (or securities convertible into or exchangeable
for Common Stock) at a price per share (or having a conversion or exchange
price per share, if a security convertible into or exchangeable for Common
Stock) at a price per share that is less than the Transaction Price (the
"Section 5(b) Issue Price"), then, in each case, the Exercise Price shall be
adjusted by multiplying the Exercise Price in effect immediately prior to such
record date by a fraction, the numerator of which shall be the number of
shares of Common Stock outstanding on such record date plus the number of
shares of Common Stock which the aggregate offering price of the total number
of shares of Common Stock so to be offered (or the aggregate initial
conversion or exchange price of the convertible or exchangeable securities so
to be offered) would purchase at such Current Market Price and the denominator
of which shall be the number of shares of Common Stock outstanding on such
record date plus the number of additional shares of Common Stock to be offered
for subscription or purchase (or into which the convertible or exchangeable
securities so to be offered are initially convertible or exchangeable);
provided, however, that no adjustment shall be made for the issuance by the
Company of any equity securities pursuant to the provisions of any of the
Company's currently outstanding "J" Warrants. Subject to the foregoing, such
adjustment shall be made successively whenever any event listed above shall
occur provided, however, that no such adjustment shall be made which results
in an increase in the Exercise Price. Such adjustment shall become effective
at the close of business on such record date; provided, however, that, to the
extent the shares of Common Stock (or securities convertible into or
exchangeable for shares of Common Stock) are not delivered, the Exercise Price
shall be readjusted after the expiration of such rights, options, or warrants
(but only with respect to Warrants exercised after such expiration), to the
Exercise Price which would then be in effect had the adjustments made upon the
issuance of such rights, options, or warrants been made upon the basis of
delivery of only the number of shares of Common Stock (or securities
convertible into or exchangeable for shares of Common Stock) actually issued.
In case any subscription price may be paid in a consideration part or all of
which shall be in a form other than cash, the value of such consideration
shall be as determined in good faith by the board of directors of the Company,
whose determination shall be conclusive absent manifest error. Shares of
Common Stock owned by or held for the account of the Company or any
majority-owned subsidiary shall not be deemed outstanding for the purpose of
any such computation.
(c) In case the Company shall distribute to all holders of Common
Stock (including any such distribution made to the stockholders of the Company
in connection with a consolidation or merger in which the Company is the
continuing corporation) evidences of its indebtedness, cash or assets (other
than distributions and dividends payable in shares of Common Stock), or
rights, options, or warrants to subscribe for or purchase Common Stock, or
securities convertible into or changeable for shares of Common Stock
(excluding those with respect to the issuance of which an adjustment of the
Exercise Price is provided pursuant to Section 5(b) hereof), then, in each
case, the Exercise Price shall be adjusted by multiplying the Exercise Price
in effect immediately prior to the record date for the determination of
stockholders entitled to receive such distribution by a fraction, the
numerator of which shall be the Current Market Price per share of Common Stock
on such record date, less the fair market value applicable to one share (as
determined in good faith by the board of directors of the Company, whose
determination shall be conclusive absent manifest error) of the portion of the
evidences of indebtedness or assets so to be distributed, or of such rights,
options, or warrants or convertible or exchangeable securities, or the amount
of such cash; and the denominator of which shall be such Current Market Price
per share of Common Stock. Such adjustment shall become effective at the
close of business on such record date.
(d) In case the Company shall issue shares of Common Stock or
rights, options, or warrants to subscribe for or purchase Common Stock, or
securities convertible into or exchangeable for Common Stock (excluding
shares, rights, options, warrants, or convertible or exchangeable securities
issued or issuable (i) in any of the transactions with respect to which an
adjustment of the Exercise Price is provided pursuant to Sections 5(a), 5(b),
or 5(c) above, or (ii) upon exercise of this Warrant) at a price per share
that is less than the Transaction Price (the "Section 5(d) Exercise Price"),
(determined, in the case of such rights, options, warrants, or convertible or
exchangeable securities, by dividing (x) the total amount received or
receivable by the Company in consideration of the sale and issuance of such
rights, options, warrants, or convertible or exchangeable securities, plus the
minimum aggregate consideration payable to the Company upon exercise,
conversion, or exchange thereof, by (y) the maximum number of shares covered
by such rights, options, warrants, or convertible or exchangeable securities)
then the Exercise Price shall be reduced on the date of such issuance to a
price (calculated to the nearest cent) determined by multiplying the Exercise
Price in effect immediately prior to such issuance by a fraction, (1) the
numerator of which shall be an amount equal to the sum of (A) the number of
shares of Common Stock outstanding immediately prior to such issuance plus (B)
the quotient obtained by dividing the consideration received by the Company
upon such issuance by such Current Market Price, and (2) the denominator of
which shall be the total number of shares of Common Stock outstanding
immediately after such issuance; provided, however, that no such adjustment
shall be made which results in an increase in the Exercise Price. For the
purposes of such adjustments, the maximum number of shares which the holders
of any such rights, options, warrants, or convertible or exchangeable
securities shall be entitled to initially subscribe for or purchase or convert
or exchange such securities into shall be deemed to be issued and outstanding
as of the date of such issuance, and the consideration received by the Company
therefor shall be deemed to be the consideration received by the Company for
such rights, options, warrants, or convertible or exchangeable securities,
plus the minimum aggregate consideration or premiums stated in such rights,
options, warrants, or convertible or exchangeable securities to be paid for
the shares covered thereby. No further adjustment of the Exercise Price shall
be made as a result of the actual issuance of shares of Common Stock on
exercise of such rights, options, or warrants or on conversion or exchange of
such convertible or exchangeable securities. On the expiration or the
termination of such rights, options, or warrants, or the termination of such
right to convert or exchange, the Exercise Price shall be readjusted (but only
with respect to this Warrant if exercised after such expiration or
termination) to such Exercise Price as would have been obtained had the
adjustments made upon the issuance of such rights, options, warrants, or
convertible or exchangeable securities been made upon the basis of the
delivery of only the number of shares of Common Stock actually delivered upon
the exercise of such rights, options, or warrants or upon the conversion or
exchange of any such securities; and on any change of the number of shares of
Common Stock deliverable upon the exercise of any such rights, options, or
warrants or conversion or exchange of such convertible or exchangeable
securities or any change in the consideration to be received by the Company
upon such exercise, conversion, or exchange, including, without limitation, a
change resulting from the antidilution provisions thereof. In case the
Company shall issue shares of Common Stock or any such rights, options,
warrants, or convertible or exchangeable securities for a consideration
consisting, in whole or in part, of property other than cash or its
equivalent, then the "price per share" and the "consideration received by the
Company" for purposes of the first sentence of this Section 5(d) shall be as
determined in good faith by the board of directors of the Company, whose
determination shall be conclusive absent manifest error. Shares of Common
Stock owned by or held for the account of the Company or any majority-owned
subsidiary shall not be deemed outstanding for the purpose of any such
computation.
(e) In any case in which this Section 5 shall require that an
adjustment in the Exercise Price be made effective as of a record date for a
specified event, the Company may elect to defer, until the occurrence of such
event, issuing to the Holder, if the Holder exercised this Warrant after such
record date, the shares of Common Stock, if any, issuable upon such exercise
over and above the shares of Common Stock, if any, issuable upon such exercise
on the basis of the Exercise Price in effect prior to such adjustment;
provided, however, that the Company shall deliver to the Holder a due ▇▇▇▇ or
other appropriate instrument evidencing the Holder's right to receive such
additional shares upon the occurrence of the event requiring such adjustment.
(f) Upon each adjustment of the Exercise Price as a result of the
calculations made in Sections 5(b), 5(c), or 5(d) hereof, this Warrant shall
thereafter evidence the right to purchase, at the adjusted Exercise Price,
that number of shares (calculated to the nearest thousandth) obtained by
dividing (A) the Exercise Price in effect prior to adjustment of the Exercise
Price by (B) the Exercise Price in effect after such adjustment of the
Exercise Price, and multiplying the result by the number of shares purchasable
upon exercise of this Warrant prior to adjustment.
(g) Whenever there shall be an adjustment as provided in this
Section 5, the Company shall promptly cause written notice thereof to be sent
by certified mail, postage prepaid, to the Holder, at its address as it shall
appear in the Warrant Register, which notice shall be accompanied by an
officer's certificate setting forth the number of Warrant Shares purchasable
upon the exercise of this Warrant and the Exercise Price after such adjustment
and setting forth a brief statement of the facts requiring such adjustment and
the computation thereof, which officer's certificate shall be conclusive
evidence of the correctness of any such adjustment absent manifest error.
(h) The Company shall not be required to issue fractions of
shares of Common Stock or other capital stock of the Company upon the exercise
of this Warrant. If any fraction of a share would be issuable on the exercise
of this Warrant (or specified portions thereof), the Company shall purchase
such fraction for an amount in cash equal to the same fraction of the Current
Market Price of such share of Common Stock on the date of exercise of this
Warrant.
6. (a) In case of any consolidation with or merger of the Company with
or into another corporation (other than a merger or consolidation in which the
Company is the surviving or continuing corporation), or in case of any sale,
lease, or conveyance to another corporation of the property and assets of any
nature of the Company as an entirety or substantially as an entirety, such
successor, leasing, or purchasing corporation, as the case may be, shall (i)
execute with the Holder an agreement providing that the Holder shall have the
right thereafter to receive upon exercise of this Warrant solely the kind and
amount of shares of stock and other securities, property, cash, or any
combination thereof receivable upon such consolidation, merger, sale, lease,
or conveyance by a holder of the number of shares of Common Stock for which
this Warrant might have been exercised immediately prior to such
consolidation, merger, sale, lease, or conveyance, and (ii) make effective
provisions in its certificate of incorporation or otherwise, if necessary, to
effect such agreement. Such agreement shall provide for adjustments which
shall be as nearly equivalent as practicable to the adjustments in Section 5.
(b) In case of any reclassification or change of the shares of
Common Stock issuable upon exercise of this Warrant (other than a change in
par value or from no par value to a specified par value, or as a result of a
subdivision or combination, but including any change in the shares into two or
more classes or series of shares), or in case of any consolidation or merger
of another corporation into the Company in which the Company is the continuing
corporation and in which there is a reclassification or change (including a
change to the right to receive cash or other property) of the shares of Common
Stock (other than a change in par value, or from no par value to a specified
par value, or as a result of a subdivision or combination, but including any
change in the shares into two or more classes or series of shares), the Holder
shall have the right thereafter to receive upon exercise of this Warrant
solely the kind and amount of shares of stock and other securities, property,
cash, or any combination thereof receivable upon such reclassification,
change, consolidation, or merger by a holder of the number of shares of Common
Stock for which this Warrant might have been exercised immediately prior to
such reclassification, change, consolidation, or merger. Thereafter,
appropriate provision shall be made for adjustments which shall be as nearly
equivalent as practicable to the adjustments in Section 5.
(c) The above provisions of this Section 6 shall similarly apply
to successive reclassifications and changes of shares of Common Stock and to
successive consolidations, mergers, sales, leases, or conveyances.
7. In case at any time the Company shall propose to:
(a) pay any dividend or make any distribution on shares of Common
Stock in shares of Common Stock or make any other distribution (other than
regularly scheduled cash dividends which are not in a greater amount per share
than the most recent such cash dividend) to all holders of Common Stock; or
(b) issue any rights, warrants, or other securities to all holders
of Common Stock entitling them to purchase any additional shares of Common
Stock or any other rights, warrants, or other securities; or
(c) effect any reclassification or change of outstanding shares of
Common Stock, or any consolidation, merger, sale, lease, or conveyance of
property, described in Section 6 hereof; or
(d) effect any liquidation, dissolution, or winding-up of the
Company; or
(e) take any other action which would cause an adjustment to the
Exercise Price;
then, and in any one or more of such cases, the Company shall give written
notice thereof, by certified mail, postage prepaid, to the Holder at the
Holder's address as it shall appear in the Warrant Register, mailed at least
fifteen (15) days prior to (i) the date as of which the holders of record of
shares of Common Stock to be entitled to receive any such dividend,
distribution, rights, warrants, or other securities are to be determined, (ii)
the date on which any such reclassification, change of outstanding shares of
Common Stock, consolidation, merger, sale, lease, conveyance of property,
liquidation, dissolution, or winding-up is expected to become effective, and
the date as of which it is expected that holders of record of shares of Common
Stock shall be entitled to exchange their shares for securities or other
property, if any, deliverable upon such reclassification, change of
outstanding shares, consolidation, merger, sale, lease, conveyance of
property, liquidation, dissolution, or winding-up, or (iii) the date of such
other action which would require an adjustment to the Exercise Price.
8. The issuance of any shares or other securities upon the exercise of
this Warrant, and the delivery of certificates or other instruments
representing such shares or other securities, shall be made without charge to
the Holder for any tax or other charge in respect of such issuance. The
Company shall not, however, be required to pay any tax which may be payable in
respect of any transfer involved in the issue and delivery of any certificate
in a name other than that of the Holder and the Company shall not be required
to issue or deliver any such certificate unless and until the person or
persons requesting the issue thereof shall have paid to the Company the amount
of such tax or shall have established to the satisfaction of the Company that
such tax has been paid.
9. The Company and the Holder acknowledge and agree that Shares issuable
upon exercise of this Warrant pursuant to Section 1 hereof shall have the
benefit of the registration rights set forth in the Registration Rights
Agreement.
10. Unless the qualifications set forth in the legend have been
satisfied with respect to the Warrant Shares, the Warrant Shares issued upon
exercise of this Warrant shall be subject to a stop transfer order and the
certificate or certificates evidencing such Warrant Shares shall bear the
following legend:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
"ACT"), OR ANY STATE SECURITIES LAWS AND NEITHER SUCH SECURITIES
NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED
OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH
RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE
STATE SECURITIES LAWS OR (2) THE COMPANY RECEIVES AN OPINION OF
COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH OPINION IS
REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY
BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER
CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
ACT OR APPLICABLE STATE SECURITIES LAWS."
11. Upon receipt of evidence satisfactory to the Company of the loss,
theft, destruction, or mutilation of this Warrant (and upon surrender of any
Warrant if mutilated), including an affidavit of the Holder that this Warrant
has been lost, stolen, destroyed or mutilated, together with an indemnity
against any claim that may be made against the Company on account of such
lost, stolen, destroyed or mutilated Warrant, and upon reimbursement of the
Company's reasonable incidental expenses, the Company shall execute and
deliver to the Holder a new Warrant of like date, tenor, and denomination.
12. The Holder of this Warrant shall not have solely on account of such
status, any rights of a stockholder of the Company, either at law or in
equity, or to any notice of meetings of stockholders or of any other
proceedings of the Company, except as provided in this Warrant.
13. Neither the Holder nor any of its affiliates, agents, successors or
assigns shall engage in any short sales of the Company's securities during the
term of this Warrant. In the event that any such person engages in short
sales of the Company's securities against the future delivery of any pro rata
share of the Company's securities pursuant to a Registration Statement or
otherwise, the Company shall be entitled to take any actions it deems
necessary or appropriate with respect to the registration of such securities
and to post stop transfer instructions with respect to any of the Company's
securities held by such person.
14. This Warrant shall be governed by and construed in accordance with
the laws of the State of New York, without giving effect to principles
governing conflicts of law.
15. The Company irrevocably consents to the jurisdiction of the courts
of the State of New York and of any federal court located in such State in
connection with any action or proceeding arising out of or relating to this
Warrant, any document or instrument delivered pursuant to, in connection with
or simultaneously with this Warrant, or a breach of this Warrant or any such
document or instrument. In any such action or proceeding, the Company waives
personal service of any summons, complaint or other process and agrees that
service thereof may be made in accordance with Section 16 of this Warrant.
Within thirty (30) days after such service, or such other time as may be
mutually agreed upon in writing by the attorneys for the parties to such
action or proceeding, the Company shall appear to answer such summons,
complaint or other process.
16. Any notice or other communication required or permitted to be given
hereunder shall be in writing and shall be mailed by certified mail, return
receipt requested, or by Federal Express, or similar overnight delivery or
courier service or delivered (in person or by telecopy, telex or similar
telecommunications equipment) against receipt to the party to whom it is to be
given, (i) if to the Company, at its address stated in Section 1 hereof, (ii)
if to the Holder, at its address set forth on the first page hereof, or (iii)
in either case, to such other address as the party shall have furnished in
writing in accordance with the provisions of this Section 16. Any notice or
other communication given by certified mail shall be deemed given at the time
of certification thereof, except for a notice changing a party's address which
shall be deemed given at the time of receipt thereof. Any notice given by
other means permitted by this Section 16 shall be deemed given at the time of
receipt thereof.
17. No course of dealing and no delay or omission on the part of the
Holder in exercising any right or remedy shall operate as a waiver thereof or
otherwise prejudice the Holder's rights, powers or remedies. No right, power
or remedy conferred by this Warrant upon the Holder shall be exclusive of any
other right, power or remedy referred to herein or now or hereafter available
at law, in equity, by statute or otherwise, and all such remedies may be
exercised singly or concurrently.
18. This Warrant may be amended only by a written instrument executed by
the Company and the Holder hereof. Any amendment shall be endorsed upon this
Warrant, and all future Holders shall be bound thereby.
Dated: As of January 10, 2002
BION ENVIRONMENTAL TECHNOLOGIES, INC.
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: CEO
[Seal]
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇
-----------------------------
Name: ▇▇▇▇▇ ▇▇▇▇▇▇
Title: Assistant Secretary
FORM OF ASSIGNMENT
(To be executed by the registered holder if such holder desires to transfer
the attached Warrant.)
FOR VALUE RECEIVED, _____________________ hereby sells, assigns, and
transfers unto _________________ a Warrant to purchase __________ shares of
Common Stock, no par value per share, of Infinity, Inc. (the "Company"),
together with all right, title, and interest therein, and does hereby
irrevocably constitute and appoint ___________________ attorney to transfer
such Warrant on the books of the Company, with full power of substitution.
Dated: _________________
Signature_____________________________
______________________________________
Signature Guarantee
NOTICE
The signature on the foregoing Assignment must correspond to the name as
written upon the face of this Warrant in every particular, without alteration
or enlargement or any change whatsoever.
To: Bion Environmental Technologies, Inc.
▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
ELECTION TO EXERCISE
The undersigned hereby exercises his or its rights to purchase _______
Warrant Shares covered by the within Warrant, and tenders payment herewith in
the aggregate amount of $________, including (i) $_______ by certified or bank
cashier's check, and/or (ii) cashless exercise of Warrants to purchase ___
Warrant Shares, in accordance with the terms thereof, and requests that
certificates for such securities be issued in the name of, and delivered to:
________________________________________________________________
________________________________________________________________
________________________________________________________________
(Print Name, Address and Social Security
or Tax Identification Number)
and, if such number of Warrant Shares shall not be all the Warrant Shares
covered by the within Warrant and the remaining portion of the within Warrant
be not cancelled in payment of the Exercise Price, that a new Warrant for the
balance of the Warrant Shares covered by the within Warrant be registered in
the name of, and delivered to, the undersigned at the address stated below.
________________________________________________________________
________________________________________________________________
________________________________________________________________
(Print Name, Address and Social Security
or Tax Identification Number)
Dated: ______________________ Name:________________________
(Print)
Address:________________________________________________________
_____________________________
(Signature)
_____________________________
(Signature Guarantee)
_____________________________
(Signature Guarantee)
EXHIBIT B
REGISTRATION RIGHTS AGREEMENT
This REGISTRATION RIGHTS AGREEMENT (this "Agreement") is entered into as
of January 10, 2002 by and among Bion Environmental Technologies, Inc., a
Colorado corporation (the "Issuer"), and OAM S.p.A., an Italian corporation
("OAM"). The Issuer and OAM are sometimes referred to herein collectively as
the "Parties" or each individually as a "Party".
WHEREAS, in connection with the Stock Purchase Agreement of even date
herewith by and between the Parties hereto (the "Stock Purchase Agreement"),
the Issuer has agreed, upon the terms and subject to the conditions of the
Stock Purchase Agreement, to issue to OAM 1,000,000 shares of Common Stock and
pursuant to Section 1.1 of the Stock Purchase Agreement to issue 1,000,000
additional shares of Common Stock to OAM pursuant to a Warrant (the "Warrant")
of even date herewith (collectively, the "Registrable Securities"); and
WHEREAS, to induce OAM to execute and deliver the Stock Purchase
Agreement, the Issuer agreed to provide certain registration rights under the
Securities Act (as defined below) for the Registrable Securities.
NOW, THEREFORE, in consideration of the premises and mutual covenants
and obligations hereafter set forth and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties,
intending to be legally bound, hereby agree as follows:
1. Registration Rights.
1.1 Certain Definitions. As used in this Agreement, the following
terms shall have the following respective meanings:
(a) "Commission" shall mean the United States Securities and
Exchange Commission or any other federal agency at the time administering the
Securities Act and the Exchange Act.
(b) "Common Stock" shall mean the Issuer's common stock, no
par value per share.
(c) "Exchange Act" shall mean the Securities Exchange Act of
1934, as amended, or any similar federal statute and the rules and regulations
of the Commission thereunder, all as the same shall be in effect at the time.
(d) "Holder" shall mean OAM or any direct or indirect
transferee of OAM or another Holder, with respect to the Registrable
Securities so transferred.
(e) "Person" shall mean a corporation, a limited liability
company, an association, a partnership, an organization, a business, a trust,
an individual, a governmental or political subdivision thereof or a
governmental agency.
(f) The terms "register," "registered" and "registration"
refer to a registration effected by preparing and filing a Registration
Statement in compliance with the Securities Act, and the declaration or
ordering of the effectiveness of such Registration Statement by the
Commission.
(g) "Registration Expenses" shall mean all expenses, except
as otherwise stated below, incurred by the Issuer in complying with Sections
1.2 and 1.3 hereof, including, without limitation, all registration,
qualification and filing fees, indenture trustee fees and expenses and other
customary third party fees and expenses in connection with facilitating the
public trading of the Common Stock, printing expenses, escrow fees, fees and
disbursements of counsel for the Issuer, reasonable fees and disbursements of
the Holders' Counsel (as defined in Section 1.5(b)), "blue sky" fees and
expenses and the expense of any special audits incident to or required by any
such registration (but excluding the compensation of regular employees of the
Issuer which shall be paid in any event by the Issuer). Registration Expenses
shall not include Selling Expenses.
(h) "Registration Statement" shall mean any registration
statement which covers any of the Registrable Securities pursuant to the
provisions of this Agreement, including the prospectus included therein, all
amendments and supplements to such Registration Statement, including
post-effective amendments, all exhibits and all material incorporated by
reference in such Registration Statement.
(i) "Rule 144" shall mean Rule 144 promulgated under the
Securities Act or any successor rule thereto or any complementary rule thereto
(such as Rule 144A).
(j) "Securities Act" shall mean the Securities Act of 1933,
as amended, or any similar federal statute and the rules and regulations of
the Commission thereunder, all as the same shall be in effect at the time.
(k) "Selling Expenses" shall mean all underwriting
discounts, selling commissions and stock transfer taxes applicable to the
securities registered by the Holders and all reasonable fees and disbursements
of counsel for the selling Holders (other than those included in Registration
Expenses).
1.2 Registration.
(a) Registration. The Issuer shall file with the Commission
a Registration Statement effecting the registration of the Registrable
Securities under the Securities Act at the earliest practicable date and
within 90 days of the date of Centerpoint Corporation's filing with the SEC of
its Form 10-K with audited financial statements for the year ended December
31, 2001 ("Centerpoint Form 10-K") and shall exert its best efforts to cause
such Registration Statement to be declared effective as soon as practicable
thereafter; provided, however, that should the Commission allow the
Registration Statement to be filed and declared effective without the
Centerpoint Form10-K being filed and without including therein the Centerpoint
audited financial statements for the year ended December 31, 2001, the Issuer
shall be required to file the Registration Statement at the earliest
practicable date and within 90 days of the date that such determination is
made by the Commission's staff. The Issuer shall use its best efforts to
maintain the effectiveness of the Registration Statement for a period of
three years from the date of exercise of the Warrant or the date on which all
of the Holders of the Registrable Securities meet all of the technical
requirements to be able to sell the Registrable Securities in reliance upon
the provisions of Rule 144(k) promulgated under the Securities Act of 1933.
If necessary, the Issuer shall cause to be filed, and shall use its best
efforts to have declared effective as soon as practicable following filing,
additional registration statements or amendments necessary to maintain such
effectiveness for such three year period. Issuer shall cause Centerpoint's
Form 10-K to be filed as soon as is reasonably practicable and shall use its
best efforts to cause Centerpoint's Form 10-K to be filed within 90 days of
the date hereof.
(b) Failure to Register or Lapse in Effectiveness.
(i) The parties acknowledge and agree that the
covenants and agreements set forth in Section 1.2(a) are an essential
inducement to OAM's purchasing the Registrable Securities and that if such
covenants and agreements are breached, OAM would be deprived of the benefits
of its bargain. The provisions of this Section 1.2 shall be in addition to
and not in lieu of any other equitable or legal remedies available to the
Holders in respect of any breach by the Issuer of Section 1.2 hereof.
(ii) In the event that the Issuer fails to file with
the Commission a Registration Statement effecting the registration of the
Registrable Securities under the Securities Act within 90 days of the date of
Centerpoint Corporation's filing with the SEC of its Form 10-K (the "Filing
Deadline"), the Issuer shall pay to the Holder a penalty in shares of Issuer's
Common Stock an amount equal to five percent (5%) of the outstanding shares of
Issuer Common Stock held by Holder for each ninety day period after the Filing
Deadline that such Registration Statement is not filed.
(iii) In the event that such Registration Statement is
not declared effective by the Commission within nine months of the date of its
initial filing (the "Effectiveness Deadline"), the Issuer shall pay to the
Holder a penalty in shares of Issuer's Common Stock an amount equal to five
percent (5%) of the outstanding shares of Issuer Common Stock held by Holder
for each ninety day period after the Effectiveness Deadline that such
Registration Statement is not declared effective by the Commission; provided,
however, that the Issuer shall not be required to pay any penalty hereunder if
the failure to have such Registration Statement declared effective by the
Effectiveness Deadline is due solely to disclosure issues related directly to
Centerpoint Corporation during the time period prior to Closing that the
Issuer is unable to resolve with the Commission despite the Issuer's best
efforts to have the Registration Statement declared effective as soon as
practicable following the filing.
(c) The Issuer may, at its option, in satisfaction of its
obligation to file the Registration Statement in (a) above, amend its Form S-2
Registration Statement dated October 26, 2001 to cause the Registrable
Securities to be included in such registration statement, within the time
periods set forth in (a) above, in which event all references in this
Agreement to the Registration Statement shall mean such registration statement
as amended, and as amended from time to time.
1.3 Expenses of Registration. All Registration Expenses shall be
borne by the Issuer. All Selling Expenses relating to securities registered
on behalf of the Holder shall be borne by the Holders of such securities pro
rata on the basis of the number of securities so registered.
1.4 Registration Procedures. In the case of each registration,
qualification or compliance effected by the Issuer pursuant to this Section 1,
the Issuer will keep each Holder advised in writing as to the initiation of
each registration and such amendment thereof and as to the effectiveness
thereof. At its expense the Issuer will:
(a) Promptly prepare and file with the Commission a
Registration Statement with respect to such securities and use its best
efforts to cause such Registration Statement to become effective as promptly
as is reasonably practicable, subject, however, to the provisions of Section
1.5 of this Agreement, and remain effective for the period provided in
Section 1.2 (the "Registration Period"); provided, however, that if, after
such Registration Statement has become effective, the offering of the
Registrable Securities pursuant to such registration is interfered with by any
stop order, injunction or similar order of the Commission or other
governmental agency or court (an "Order"), such registration will be deemed
not to have been effected except to any Holder whose untrue statement or
omission is contained in any information or affidavit furnished in writing by
a Holder to the Issuer specifically for inclusion in such registration
statement which was the cause of such Order. Notwithstanding the foregoing,
if within sixty (60) days after the effective date of such Order, the same is
lifted and the effectiveness of the registration is restored, the registration
shall be deemed to have been effected, provided that the Registration Period
(i) will be tolled during the period the stop order, injunction or similar
order is in effect, (ii) shall resume upon the lifting thereof and (iii) shall
be extended one day for each day during the period that such Order is in
effect.
(b) Furnish, at least five (5) business days before filing a
Registration Statement that registers such Registrable Securities, a
prospectus relating thereto and any amendments or supplements relating to such
a Registration Statement or prospectus, to one counsel selected by the Holders
(the "Holders' Counsel"), copies of all such documents proposed to be filed
(it being understood that such five-business-day period need not apply to
successive drafts of the same document proposed to be filed so long as such
successive drafts are supplied to the Holders' Counsel in advance of the
proposed filing by a period of time that is customary and reasonable under the
circumstances).
(c) Prepare and file with the Commission such amendments and
supplements to such Registration Statement and the prospectus used in
connection with such Registration Statement as may be necessary to keep such
Registration Statement effective for the Registration Period, and to comply
with the provisions of the Securities Act with respect to the sale and other
disposition of all securities covered by such Registration Statement.
(d) Notify in writing to the Holders' Counsel promptly (i)
of the receipt by the Issuer of any notification with respect to any comments
by the Commission with respect to such Registration Statement or prospectus or
any amendment or supplement thereto or any request by the Commission for the
amending or supplementing thereof or for additional information with respect
thereto, (ii) of the receipt by the Issuer of any notification with respect to
the issuance by the Commission of any stop order suspending the effectiveness
of such Registration Statement or prospectus or any amendment or supplement
thereto or the initiation or threatening of any proceeding for that purpose
and (iii) of the receipt by the Issuer of any notification with respect to the
suspension of the qualification of such Registrable Securities for sale in any
jurisdiction or the initiation or threatening of any proceeding for such
purposes.
(e) Use its best efforts to register and qualify the
securities covered by such Registration Statement under such other securities
or "blue sky" laws of such jurisdictions as shall be reasonably requested by
the Holders, provided that the Issuer shall not be required in connection
therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions.
(f) Furnish to the Holders participating in such
registration and to the underwriters of the securities being registered such
number of copies of the Registration Statement, preliminary prospectus, final
prospectus and such other documents as such Holders or underwriters may
reasonably request in order to facilitate the public offering of such
securities.
(g) In the event of any underwritten public offering, enter
into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each Holder
participating in such underwriting shall also enter into and perform its
obligations under such an agreement.
(h) Notify each Holder of Registrable Securities covered by
such Registration Statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any
event as a result of which the prospectus included in such Registration
Statement, as then in effect, includes an untrue statement of a material fact
or omits to state a material fact required to be stated therein or necessary
to make the statements therein not misleading in the light of the
circumstances then existing.
(i) Use its best efforts to furnish, at the request of any
Holder requesting registration of Registrable Securities pursuant to this
Section 1, on the date that such Registrable Securities are delivered to the
underwriters for sale in connection with a registration pursuant to this
Section 1, if such securities are being sold through underwriters, or, if such
securities are not being sold through underwriters, on the date that the
Registration Statement with respect to such securities becomes effective, (i)
a copy addressed to Holders of the opinion, dated such date, of the counsel
representing the Issuer for the purposes of such registration, in form and
substance as is customarily given to underwriters in an underwritten public
offering, addressed to the underwriters, if any, and (in a non-underwritten
offering) to the Holders requesting registration of Registrable Securities and
(ii) a copy addressed to Holders of the letter dated such date, from the
independent certified public accountants of the Issuer, in form and substance
as is customarily given by independent certified public accountants to
underwriters in an underwritten public offering, addressed to the
underwriters, if any, and (in a non-underwritten offering) to the Holders
requesting registration of Registrable Securities.
(j) List the Registrable Securities on any securities
exchange on which any shares of the Common Stock are listed.
(k) Otherwise use its best efforts to comply with all
applicable rules and regulations of the Commission and the securities
commission or other regulatory authority of any relevant state or other
jurisdiction and make available to its securityholders, as soon as reasonably
practicable, earnings statements (which need not be audited) covering a period
of 12 months beginning within three months after the effective date of the
Registration Statement, which earnings statements shall satisfy the provisions
of Section 11(a) of the Securities Act.
(l) Use its commercially reasonable efforts to take all
other steps reasonably necessary to effect the registration of such
Registrable Securities contemplated hereby.
1.5 Permissible Delay of Registration.
(a) If at any time or times after the Registration
Statement is declared effective by the Commission, the Issuer determines that
the disclosures in such Registration Statement contain or will contain a
misstatement of a material fact or omit or will omit to state any material
fact which would make the statements made in the Registration Statement, in
light of the circumstances under which they are made, false or misleading (a
"Disclosure Condition"), the Issuer shall be entitled to either suspend the
effectiveness of the Registration Statement with the Commission or suspend the
availability of the Registration Statement for resales of the Registrable
Securities by the Holders, or may take both such actions, and shall promptly
notify the Holder thereof by delivery of written notice (a "Suspension
Notice").
(b) Notwithstanding anything contained in subsection (a)
above to the contrary, the Issuer's obligation to maintain the Registration
Statement current under the provisions of Section 1.2 of this Agreement shall
not be suspended by reason of the Issuer's failure to disclose information at
a time when public disclosure of such information is required by law.
(c) Upon receipt of a Suspension Notice, the Holders shall
immediately discontinue the use of the Registration Statement for any purpose
until notified by the Issuer that the Shelf Registration is current and
available for use by the Holders for the resale of the Registrable Securities
held by them.
(d) The Issuer shall not be entitled to suspend the
effectiveness of the Registration Statement for a period longer than the later
of:
(i) the removal of the Disclosure Condition(s), or
(ii) a period of not more than ninety (90)
consecutive days, or
(iii) a period of not more than one hundred eighty
(180) days within any twelve (12) month period.
(e) The Issuer shall use its best efforts to cure any
Disclosure Condition(s) as quickly as is reasonably possible under the
circumstances. As soon as practicable after obtaining the information
necessary to cure the Disclosure Condition(s) or the Issuer determines that
such Disclosure Condition(s) no longer exist(s), the Issuer shall amend or
supplement the Registration Statement to the extent necessary to make the
Registration Statement current, and shall give prompt written notice to the
Holders when the Registration Statement is again available for resales of the
Registrable Securities.
1.6 Indemnification.
(a) The Issuer will indemnify each Holder and each Holder's
officers, directors, employees, principals, equity holders and partners; each
underwriter, broker or any other Person (other than the Issuer) acting on
behalf of such Holder; and each Person (other than the Issuer) controlling
such Person within the meaning of Section 15 of the Securities Act, with
respect to which registration, qualification or compliance has been effected
pursuant to this Section 1, against all expenses, claims, losses, damages or
liabilities (or actions in respect thereof) (collectively, "Losses"),
including any of the foregoing incurred in settlement of any litigation,
commenced or threatened based on (i) any untrue statement (or alleged untrue
statement) of a material fact contained in any Registration Statement,
preliminary or final prospectus, offering circular or other document, or any
amendment or supplement thereto, incident to any such registration,
qualification or compliance, or (ii) any omission (or alleged omission) to
state therein a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances in which they were
made, not misleading, or (iii) any violation by the Issuer of the Securities
Act, state securities or "blue sky" laws or any rule or regulation promulgated
thereunder applicable to the Issuer in connection with any such registration,
qualification or compliance (each statement, omission or violation referred to
in clauses (i), (ii) and (iii) of this Section 1.6(a) being referred to as a
"Violation"), and the Issuer will reimburse each such Holder, each of its
officers and directors, each such underwriter, broker or other Person (other
than the Issuer) acting on behalf of such Holder, and each such controlling
Person (other than the Issuer) for any legal and any other expenses reasonably
incurred in connection with investigating, preparing or defending any such
Loss, provided that the Issuer will not be liable to any such Holder or Person
in any such case to the extent that any such Loss arises out of or is based on
any untrue statement or omission (or alleged untrue statement or omission),
made in conformity with written information furnished to the Issuer by an
instrument duly executed by such Holder or Person and stated to be
specifically for use therein or the preparation thereby.
(b) Each Holder will, if Registrable Securities held by such
Holder are included in the securities as to which such registration,
qualification or compliance is being effected, indemnify the Issuer, each of
its directors and officers, each underwriter, broker or other Person acting on
behalf of the Issuer, and each Person who controls any of the foregoing
Persons within the meaning of Section 15 of the Securities Act, and each other
such Holder, each of its officers and directors and each person controlling
such Holder within the meaning of Section 15 of the Securities Act, against
all Losses arising out of any untrue statement (or alleged untrue statement)
of a material fact contained in any such Registration Statement, preliminary
or final prospectus, offering circular or other document, or any omission (or
alleged omission) to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, and will
reimburse the Issuer, such Holders, such directors, officers, underwriters,
brokers, other Persons acting on behalf of the Issuer or control Persons for
any legal or any other expenses reasonably incurred in connection with
investigating, preparing or defending any such Loss, in each case to the
extent, but only to the extent, that such untrue statement (or alleged untrue
statement) or omission (or alleged omission) is made in such Registration
Statement, preliminary or final prospectus, offering circular or other
document in conformity with written information furnished to the Issuer by an
instrument duly executed by such Holder and stated to be specifically for use
therein or the preparation thereby. Notwithstanding the foregoing, the
liability of each Holder under this subsection (b) shall be limited to an
amount equal to the aggregate proceeds received by such Holder from the sale
of Registrable Securities in such registration.
(c) Each Person entitled to indemnification under this
Section 1.6 (the "Indemnified Party") shall give notice to the Party required
to provide indemnification (the "Indemnifying Party") promptly after such
Indemnified Party has actual knowledge of any claim as to which indemnity may
be sought, and shall permit the Indemnifying Party to assume the defense of
any such claim or any litigation resulting therefrom, provided that counsel
for the Indemnifying Party, who shall conduct the defense of such claim or
litigation, shall be approved by the Indemnified Party (whose approval shall
not unreasonably be withheld), and the Indemnified Party may participate in
such defense at such Indemnified Party's expense, and provided further, that
the failure of any Indemnified Party to give notice as provided herein shall
not relieve the Indemnifying Party of its obligations under this Section 1.7
unless the failure to give such notice is materially prejudicial to an
Indemnifying Party's ability to defend such action and provided further, that
the Indemnifying Party shall not assume the defense for matters as to which
there is a conflict of interest or separate and different defenses. If (i)
the Indemnifying Party shall have failed to assume the defense of such claim
and to employ counsel reasonably satisfactory to the Indemnified Party in a
timely manner or (ii) in the reasonable judgment of any Indemnified Party a
conflict of interest may exist between such Indemnified Party and the
Indemnifying Party with respect to such claim, the fees and expenses of any
counsel employed by the Indemnified Party shall be at the expense of the
Indemnifying Party; provided that, if the Indemnifying Party is obligated to
pay the fees and expenses of counsel for other Indemnified Parties, such
Indemnifying Party shall be obligated to pay only the fees and expenses
associated with one attorney or law firm for the Indemnified Parties, unless
there exists a conflict of interest or separate and different defenses among
the Indemnified Parties. No Indemnifying Party, in the defense of any such
claim or litigation, shall, except with the consent of each Indemnified Party,
consent to entry of any judgment or enter into any settlement which does not
include as an unconditional term thereof the giving by the claimant or
plaintiff to such Indemnified Party of a release from all liability in respect
to such claim or litigation.
(d) If the indemnification provided for in this Section 1.6
is held by a court of competent jurisdiction to be unavailable to an
Indemnified Party with respect to any loss, claim, damage, liability or action
referred to herein, then the Indemnifying Party, in lieu of indemnifying such
Indemnified Party hereunder, shall contribute to the amounts paid or payable
by such Indemnified Party as a result of such loss, claim, damage, liability
or action in such proportion as is appropriate to reflect the relative fault
of the Indemnifying Party on the one hand and of the Indemnified Party on the
other in connection with the statements or omissions which resulted in such
loss, claim, damage, liability or action as well as any other relevant
equitable considerations. The relative fault of the Indemnifying Party and of
the Indemnified Party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information
supplied by the Indemnifying Party or by the Indemnified Party and the
parties' relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission. Notwithstanding the foregoing,
the maximum amount which any Holder shall be required to contribute pursuant
to this Section 1.6(d) shall be limited to an amount equal to the net proceeds
actually received by such Holder from the sale of Registrable Securities
effected pursuant to such registration.
1.7 Information by Holder. The Holders of securities included in
any registration shall furnish to the Issuer in writing such information
regarding such Holders, the Registrable Securities held by such Holders and
the distribution proposed by such Holders as the Issuer may reasonably request
in writing and as shall be required in connection with any registration,
qualification or compliance referred to in this Section 1.
1.8 Rule 144 Reporting. With a view to making available the
benefits of certain rules and regulations of the Commission which may at any
time permit the sale of the Registrable Securities to the public without
registration, the Issuer agrees to use its best efforts to:
(a) Make and keep public information available, as those
terms are understood and defined in Rule 144, at all times after the effective
date that the Issuer becomes subject to the reporting requirements of the
Securities Act or the Exchange Act.
(b) Use its best efforts to file with the Commission in a
timely manner all reports and other documents required of the Issuer under the
Securities Act and the Exchange Act (at any time after it has become subject
to such reporting requirements);
(c) So long as a Holder owns any Registrable Securities to
furnish to the Holder forthwith upon request a written statement by the Issuer
as to its compliance with the reporting requirements of said Rule 144, and of
the Securities Act and the Exchange Act, a copy of the most recent annual or
quarterly report of the Issuer, and such other reports and documents of the
Issuer and other information in the possession of or reasonably obtainable by
the Issuer as a Holder may reasonably request in availing itself of any rule
or regulation of the Commission allowing a Holder to sell any such securities
without registration. The Issuer will take action reasonably requested by a
Holder to facilitate the transfer of Registrable Securities pursuant to Rule
144.
1.9 Transfer of Registration Rights. The rights of each Holder
hereunder shall without any further action on the part of such Holder be
assigned and transferred to any transferee of the Registrable Securities;
provided, that immediately after the transfer, the further disposition of any
of the securities is restricted by the Securities Act; and provided further,
however, that such transferee shall, as a condition to the exercise of such
rights, be subject to the restrictions contained in this Agreement applicable
to the seller or transferor.
1.10 Prohibition Against Short Sales. None of the Holders nor any
of their respective affiliates, agents, successors or assigns shall engage in
any short sales of the Issuer's Common Stock during the term of this
Agreement. In the event that any such person engages in short sales of the
Issuer's Common Stock against the future delivery of any pro rata share of the
Registrable Securities pursuant to a Registration Statement or otherwise, the
Issuer shall be entitled to take any actions it deems necessary or appropriate
with respect to the registration of such securities and to post stop transfer
instructions with respect to any of the Issuer's shares held by such person..
2. Miscellaneous.
2.1 Governing Law; Submission to Jurisdiction.
(a) This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, without giving effect to
principles governing conflicts of law.
(b) The Parties hereto irrevocably consent to the
jurisdiction of the courts of the State of New York and of any federal court
located in the Southern District of New York in connection with any action or
proceeding arising out of or relating to this Agreement, any document or
instrument delivered pursuant to, in connection with or simultaneously with
this Agreement, or a breach of this Agreement or any such document or
instrument. In any such action or proceeding, each party hereto waives
personal service of any summons, complaint or other process and agrees that
service thereof may be made in accordance with Section 2.6. Within 30 days
after such service, or such other time as may be mutually agreed upon in
writing by the attorneys for the parties to such action or proceeding, the
party so served shall appear or answer such summons, complaint or other
process.
2.2 Survival. The representations, warranties, covenants and
agreements made herein shall survive any investigation made by any Holder, and
the closing of the transactions contemplated hereby.
2.3 Successors and Assigns. Except as otherwise provided herein,
the provisions hereof shall inure to the benefit of, and be binding upon, the
successors, assigns, heirs, executors and administrators of the Parties
hereto.
2.4 Amendments. This Agreement may only be amended by mutual
written Agreement of the parties.
2.5 Notices, etc. All notices and other communications required
or permitted hereunder shall be in writing and shall be delivered personally,
mailed by certified or registered mail, postage prepaid, return receipt
requested, by courier or facsimile (provided confirmation of transmission is
mechanically generated and kept on file by the sending party), addressed (a)
if to any Holder, at such Holder's address as set forth in the Issuer's
records, or at such other address as such Holder shall have furnished to the
Issuer in writing, (b) if to the Issuer, at ▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇,
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇, Attention: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, or at such other address
as the Issuer shall have furnished to such Holders in writing. Notices that
are mailed shall be deemed to have been given five days after deposit in the
United States mail and notices delivered personally, by facsimile or by
courier shall be deemed to have been given upon delivery to recipient's
address.
2.6 Delays or Omissions. No failure or delay by any Holder in
exercising any right, power or privilege hereunder and no course of dealing
between the Issuer, on the one hand, and any Holder, on the other hand, shall
operate as a waiver thereof; nor shall any single or partial exercise of any
right, power or privilege hereunder preclude any other or further exercise
thereof or the exercise of any other right, power or privilege hereunder. Any
Person having rights under any provision of this Agreement shall be entitled
to enforce such rights specifically or to recover damages or to exercise any
other remedy available to it at law or in equity. The foregoing rights and
remedies shall be cumulative and the exercise of any right or remedy provided
herein shall not preclude any Person from exercising any other right or remedy
provided herein. The Issuer agrees that monetary damages would not be
adequate compensation for any loss incurred by reason of a breach by it of any
of the provisions of this Agreement and hereby agrees to waive the defense in
any action for specific performance that a remedy at law would be adequate.
No notice to or demand on the Issuer in any case shall entitle the Issuer to
any other or further notice or demand in similar or other circumstances or
constitute a waiver of the rights of any Holder to any other or further action
in any circumstances without notice or demand. Each covenant contained herein
shall operate independently of any other covenant contained herein.
2.7 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.
2.8 Severability. If any provision of this Agreement, or the
application thereof, shall for any reason and to any extent be invalid or
unenforceable, the remainder of this Agreement and application of such
provision to Persons or circumstances shall be interpreted so as best to
reasonably effect the intent of the parties hereto, the parties further agree
to replace such void or unenforceable provision of this Agreement with a valid
and enforceable provision which will achieve to the extent possible, the
economic, business and other purposes of the void or unenforceable provision.
2.9 Headings. The headings in this Agreement are for convenience
of reference only and shall not limit or otherwise affect the meaning hereof.
[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
IN WITNESS WHEREOF, the parties hereto have executed this Registration
Rights Agreement as of the date first written above.
BION ENVIRONMENTAL TECHNOLOGIES, INC.
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Name ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: CEO
OAM S.p.A.
By: ▇▇▇▇ ▇▇▇▇▇▇
Name:
Title:
EXHIBIT E
OAM ASSIGNMENT OF LOAN AGREEMENT
FOR VALUE RECEIVED, Bion Environmental Technologies, Inc., a Colorado
corporation ("Assignor"), hereby sells, transfers and assigns unto OAM S.p.A.,
an Italian corporation ("OAM") ("Assignee"), as partial consideration in
connection with that certain Stock Purchase Agreement, dated the date hereof,
among Assignor and Assignee (the "Stock Purchase Agreement"), all of
Assignor's right, title and interest in and to (1) that certain Loan Agreement
dated June 13, 2001, executed by Trident Rowan Group, Inc., a Maryland
corporation ("TRG"), in favor of Assignor (the "Loan Agreement") and (2) the
Loan Documents (as defined in the Loan Agreement) including but not limited to
any rights that Assignor may have that entitle Assignor to require OAM S.p.A.,
an Italian corporation ("OAM"), to enter into a security or pledge arrangement
or agreement in connection with the Loan Agreement.
Each of Assignor and Assignee hereby agrees that the terms and
provisions of Sections 6.1, 6.4, 6.5, 6.7, 6.8, 6.9, 6.11, 6.12, 6.13, 6.14,
and 6.16 of the Stock Purchase Agreement shall be incorporated herein as if
set forth in full.
Dated: January ___, 2002
BION ENVIRONMENTAL TECHNOLOGIES, INC.
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Name:
Title:
Agreed and acknowledged:
OAM S.p.A.
By: /s/ ▇▇▇▇ ▇▇▇▇▇▇
Name:
Title:
EXHIBIT A
LOAN AGREEMENT
THIS LOAN AGREEMENT (this "Agreement") is made this 13th day of June
2001, by and between TRIDENT ROWAN GROUP, INC., a Maryland corporation,
(together with its successors and assigns, the "Borrower") and CENTERPOINT
CORPORATION, a Delaware corporation (together with its successors and assigns,
the "Lender"), with offices located c/o FDG Associates, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇
▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇.
Section 1. INTERPRETATION
(a) Definitions. The following capitalized terms are defined as
follows:
"Collateral" means the TRG Collateral and the OAM Collateral.
"Default" means any of the events set forth in Article 6 which with
giving of notice, the lapse of time, or both, would constitute an Event of
Default.
"Default Rate" means an amount equal to the Interest Rate plus two
percent (2.00%).
"Event of Default" has the meaning set forth in Article 6 hereof.
"Interest Rate" means an annual rate of interest equal to 5.00%.
"Lien" means any mortgage, pledge, hypothecation, assignment, deposit
arrangement, encumbrance, lien (statutory or other), preference, priority or
other security agreement or preferential arrangement of any kind or nature
whatsoever (including, without limitation, any conditional sale or other title
retention agreement, any financing lease having substantially the same
economic effect as any of the foregoing, and the filing of any financing
statement under the Uniform Commercial Code or comparable law of any
jurisdiction in respect of any of the foregoing). The term "Lien" shall
include reservations, exceptions, encroachments, easements, rights-of-way,
covenants, conditions, restrictions, leases and other title exceptions and
encumbrances affecting property.
"Loan" means the loan evidenced by the Note.
"Loan Documents" means this Agreement, the Note the Pledge Agreements
and the Limited Recourse Guaranty Agreement and all other documents,
instruments, financing statements, certificates and other agreements executed
in connection with the Loan.
"Note" means the Secured Promissory Note executed by the Borrower in
substantially the form of Exhibit A attached to this Agreement evidencing the
Loan.
"Limited Recourse Guaranty Agreement" means that certain Limited
Recourse Guaranty Agreement of even date herewith by and between OAM and
Lender.
"OAM" shall mean OAM, S.p.A., an Italian corporation and wholly owned
subsidiary of Borrower.
"OAM Collateral" means the Pledged Capital Stock as such term is defined
in the OAM Pledge Agreement.
"OAM Pledge Agreement" means that certain Pledge Agreement of even date
herewith by and between OAM and Lender.
"Obligations" means, without limitation, the Loan including all interest
and other charges chargeable to the Borrower or due from the Borrower to the
Lender from time to time and all costs and expenses referred to in Sections
7.4.
"Payment Dates" means the dates established pursuant to Article 2 for
the payment of interest on the Notes.
"Person" means an individual, partnership, corporation, business trust,
joint stock company, trust, unincorporated association, joint venture,
governmental authority or other entity of whatever nature.
"Pledge Agreements" means the OAM Pledge Agreement and the TRG Pledge
Agreement.
"Requirements of Law" means, with respect to any Person, any law,
treaty, rule or regulation or determination of an arbitrator or a court or
other governmental authority, in each case applicable to or binding upon such
Person or any of its property or to which such Person or any of its property
is subject.
"TRG Collateral" means the Pledged CP Capital Stock as such term is
defined in the TRG Pledge Agreement.
"TRG Pledge Agreement" means that certain Pledge Agreement of even date
herewith by and between Borrower and Lender.
"Uniform Commercial Code" or "UCC" means the Uniform Commercial Code in
each case in effect in the jurisdiction where the Collateral is located.
Section 2. LOAN TERMS AND AMOUNTS
(a) Loan Commitment. Subject to the terms and conditions of this
Agreement, the Lender hereby agrees to make a loan to Borrower in the amount
of $4,200,000. (the "Loan"). The absolute and unconditional obligation of
the Borrower to repay the Lender the principal of the Loan and the interest
thereon shall be evidenced the Note.
(b) Interest on Overdue Payments; Default Rate. If any payment of
interest or principal is not paid when due, the Lender, at its option, may
charge and collect from the Borrower interest at the Default Rate applicable
to the Note.
Upon the occurrence and during the continuance of any Event of Default,
the outstanding principal and all accrued interest as well as any other
charges due the Lender hereunder or under the Note, shall bear interest from
the date on which such amount shall have first become due and payable to the
Lender (or, in the case of other charges due Lender hereunder, five (5) days
after demand therefor by Lender) to the date on which such amount shall be
paid to the Lender (whether before or after judgment), at the Default Rate.
Upon the occurrence and during the continuance of an Event of Default, any
accrued and unpaid interest shall become and be absolutely due and payable to
the Lender, on demand, at any time. Interest will continue to accrue until
the Obligations are discharged (whether before or after judgment).
(c) Voluntary Prepayments. Borrower may voluntarily prepay, without
premium or penalty, the Loan in part or in full at any time upon notice to
Lender at least five (5) days prior to the specified prepayment date.
(d) Place of Payments. Notwithstanding anything in the Loan Documents
to the contrary, each payment payable by the Borrower to the Lender under this
Agreement or the Note shall be made directly to the Lender c/o FDG Associates,
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇ or such other place as
may be designated by Lender on the due date of each such payment in
immediately available funds.
(e) Application of Funds. The funds received by the Lender shall be
applied toward the Obligations as follows: first, to the payment of all fees,
charges and other sums (with the exception of principal and interest) due and
payable to the Lender under the Note or this Agreement at such time; second,
to the payment of interest which shall be due and payable on the principal of
the Note; and third, to the payment of principal on the Note.
Section 3. SECURITY INTEREST
To secure the payment and performance of all of the Borrower's
obligations hereunder and under the Note, the Borrower shall grant the Lender
a continuing first priority security interest in the TRG Collateral pursuant
to the TRG Pledge Agreement and shall cause its wholly owned subsidiary OAM to
grant to the Lender a continuing first priority security interest in the OAM
Collateral pursuant to the Limited Recourse Guaranty Agreement and the OAM
Pledge Agreement.
Section 4. REPRESENTATIONS AND WARRANTIES
In order to induce the Lender to enter into this Agreement, the Borrower
hereby represents and warrants to the Lender that:
(a) Enforceable Obligations. This Agreement and the Note have been duly
executed and delivered on behalf of the Borrower, and constitute the legal,
valid and binding obligation of the Borrower, enforceable against Borrower in
accordance with their terms.
(b) No Legal Bar. The execution, delivery and performance of this
Agreement and the Note, and the consummation of the transactions contemplated
hereby and thereby, will not (i) violate any Requirements of Law, or (ii)
conflict with or result in a breach of the terms or provisions of, or
constitute a default under, or (except as otherwise contemplated by any of the
Loan Documents) result in the creation of any Lien under any contractual
obligation of the Borrower.
Section 5. AFFIRMATIVE COVENANTS
So long as any Note remains outstanding and unpaid or any other
Obligation is owing to the Lender, Borrower shall promptly give notice to the
Lender of the occurrence of any Default or Event of Default setting forth the
details of the Default or Event of Default and any action taken or
contemplated to be taken with respect to the same.
Section 6. EVENTS OF DEFAULT AND REMEDIES
(a) Events of Default. The occurrence of any one or more of the
following events shall constitute an Event of Default:
(i) Payments. Failure by the Borrower to pay any interest on or
principal of the Note when it is due and payable or declared due and payable,
as the case may.
(ii) Commencement of Bankruptcy or Reorganization Proceeding. The
Borrower or OAM shall commence any case, proceeding or other action (A) under
any existing or future law of any jurisdiction, domestic or foreign, relating
to bankruptcy, insolvency, reorganization or relief of debtors, seeking to
have an order for relief entered with respect to it, or seeking to adjudicate
it as bankrupt or insolvent, or seeking reorganization, arrangement,
adjustment, wind-up, liquidation, dissolution, composition or other relief
with respect to it or its debts, or (B) seeking appointment of a receiver,
trustee, custodian or other similar official for it or for all or any
substantial part of its assets; or
There shall be commenced against the Borrower or OAM any such
case, proceeding or other action which results in the entry of an order for
relief or any such adjudication or appointment or remains undismissed,
undischarged or unbonded for a period of thirty (30) days; or
There shall be commenced against the Borrower or OAM any case,
proceeding or other action seeking issuance of a warrant of attachment,
execution, distraint or similar process against all or any substantial part of
its assets which results in the entry of an order for any such relief which
shall not have been vacated, discharged, or stayed or bonded pending appeal
within thirty (30) days from the entry thereof.
(b) Remedies. Upon the occurrence of an Event of Default described in
this Article 6, the Lender, at its option, may:
(i) declare the Obligations of the Borrower immediately due and
payable, without presentment, notice, protest or demand of any kind for the
payment of all or any part of the Obligations (all of which are expressly
waived by the Borrower) and exercise all of its rights and remedies against
the Borrower and any Collateral provided herein or in any other agreement
between the Borrower and the Lender, and
(ii) exercise all rights granted to it under the Pledge Agreement.
(c) Application of Proceeds. The Lender shall apply any credit in
respect of disposition of the Collateral to the payment of the Obligations in
accordance with the provisions of Section 2.5 hereof.
(d) Rights Cumulative; Waiver. The rights, options and remedies of the
Lender shall be cumulative and no failure or delay by the Lender in exercising
any right, option or remedy shall be deemed a waiver thereof or of any other
right, option or remedy, or waiver of any Event of Default hereunder, nor
shall any single or partial exercise of any such right, power or remedy
preclude any other or further exercise thereof or the exercise of any other
right, power or remedy hereunder. The Lender shall not be deemed to have
waived any of the Lender's rights hereunder or under any other agreement,
instrument or paper signed by the Borrower unless such waiver shall be in
writing and signed by the Lender in accordance with the provisions hereof.
Section 7. MISCELLANEOUS
(a) Amendments and Waivers. Borrower and Lender may amend this
Agreement or the Note, and the Lender may waive future compliance by the
Borrower with any provision of this Agreement or the Note, but no such
amendment or waiver shall be effective unless in a written instrument executed
by an authorized officer of the Lender and Borrower.
(b) Notices. All notices, consents, requests and demands to or upon the
respective parties hereto shall be in writing and, unless otherwise expressly
provided herein, shall be deemed to have been duly given or made when
delivered by hand, or when deposited in the mail, postage prepaid, or, in the
case of telex, telegraphic or telecopy notice, when sent, addressed as
follows:
If to the Lender: Centerpoint Corporation
c/o FDG Associates
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Facsimile No.: (▇▇▇) ▇▇▇-▇▇▇▇ or
(▇▇▇) ▇▇▇-▇▇▇▇
If to the Borrower: Trident Rowan Group, Inc.
c/o FDG Associates
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Facsimile No.: (▇▇▇) ▇▇▇-▇▇▇▇ or
(▇▇▇) ▇▇▇-▇▇▇▇
Notices of changes of address shall be given in the same manner.
(c) Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the Borrower, the Lender and their respective
successors and assigns, except that the Borrower may not assign or transfer
any of its rights or obligations under this Agreement without the prior
written consent of the Lender. If the Lender shall transfer its Note and its
rights under this Agreement, then the Lender shall be relieved and released
from its obligations hereunder.
(d) Collection Costs. All reasonable costs and expenses incurred by the
Lender to obtain, enforce or preserve the security interests granted by this
Agreement and to collect the Obligations, including, without limitation, all
reasonable out-of-pocket costs, all reasonable costs to maintain and preserve
the Collateral and all reasonable attorneys' fees and legal expenses incurred
in obtaining or enforcing payment of any of the Obligations or foreclosing the
Lender's security interest in any of the Collateral, whether through judicial
proceedings or otherwise, or in enforcing or protecting its rights and
interests under this Agreement or under any other instrument or document
delivered pursuant hereto, or in protecting the rights of any holder or
holders with respect thereto, or in defending or prosecuting any actions or
proceedings arising out of or relating to the Lender's transactions with the
Borrower shall become part of the Obligations, and the Lender may take
judgment against the Borrower for all such costs, expenses and fees in
addition to all other amounts due from the Borrower hereunder.
(e) Counterparts. This Agreement may be executed by one or more of the
parties to this Agreement on any number of separate counterparts and all of
said counterparts taken together shall be deemed to constitute one and the
same instrument.
(f) Governing Law. This Agreement, the Note and the other Loan
Documents and the rights and obligations of the parties under this Agreement,
the Note and the other Loan Documents shall be governed by, and construed and
interpreted in accordance with, the laws of the State of New York, without
regard to its statues relating to conflicts of laws.
(g) WAIVER OF JURY TRIAL. AS A SPECIFICALLY BARGAINED INDUCEMENT FOR
THE LENDER TO EXTEND CREDIT TO THE BORROWER, AND AFTER HAVING THE OPPORTUNITY
TO CONSULT COUNSEL, THE BORROWER HEREBY EXPRESSLY WAIVES THE RIGHT TO TRIAL BY
JURY IN ANY LAWSUIT OR PROCEEDING RELATING TO THIS AGREEMENT OR ARISING IN ANY
WAY FROM THE OBLIGATIONS.
(h) Other Waivers. Borrower waives notice of nonpayment, demand, notice
of demand, presentment, protest and notice of protest with respect to the
Obligations, or notice of acceptance hereof, notice of the Loan made, credit
extended, Collateral received or delivered, or any other action taken in
reliance hereon, and all other demands and notices of any description, except
such as are expressly provided for herein.
[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
IN WITNESS WHEREOF, the parties have duly executed this Agreement as of
the date first above written.
BORROWER:
TRIDENT ROWAN GROUP, INC.
By:
Name:
Title:
LENDER:
CENTERPOINT CORPORATION
By:
Name:
Title:
Schedule A
Term Note
Payment Schedule
Interest Payments due semi-annually on January 14, 2002 and upon
repayment of principal. Principal due and payable on June 13, 2002
EXHIBIT F
ASSIGNMENT OF ASSIGNMENT
OF ESCROW AGREEMENT
AGREEMENT (this "Agreement"), made as of this 10th day of January, 2002
by and between Bion Environmental Technologies, Inc., a Colorado corporation
('Bion') and OAM S.p.A., an Italian corporation ('OAM' and together with Bion,
the "Parties").
WHEREAS, Pursuant to the terms of the Share Purchase Agreement dated
April 14, 2000 by and between Centerpoint Corporation ("Centerpoint") and
Aprilia, S.p.A. ("Aprilia") and the related Escrow Agreement relating to the
sale of Moto Guzzi's operating subsidiaries, Lit. 9,375 million of the
proceeds of the sale were placed into escrow;
WHEREAS, by letter dated July 13, 2001 Aprilia requested that Banca di
Intermediazione Mobiliare IMI S.p.A., the escrow agent under the Escrow
Agreement ("IMI"), pay them Lit. 7,611 million in respect of claims alleged by
it in June 2000 and on July 26, 2001, in spite of being aware of Centerpoint
contesting of each of the alleged claims and its intention to seek
arbitration, IMI advised Centerpoint that it had paid Lit. 7,611 million from
the escrow account to Aprilia in respect of the Alleged Claims;
WHEREAS, Bion has on this date acquired from Centerpoint, pursuant to
that certain Assignment of Escrow agreement, dted the date hereof, between
Bion and Centerpoint (the "Assignment of Agreement"), a 65% interest in and to
the Escrow Agreement and the Abitration, and 65% of all claims, including
Centerpoint's right to receive principal, interest, fees, expenses, damages,
penalties and other amounts in respect of, or in connection with, any of the
foregoing, together with voting and other rights and benefits arising from,
under or relating to any of the foregoing, including, without limitation, all
of Centerpoint?s rights to receive cash, securities, instruments and/or other
property or distributions issued in connection with any of the foregoing
(collectively, "Bion's Assigned Interest"); and
WHEREAS, Bion and OAM are entering into that certain Stock Purchase
Agreement, dated the date hereof (the "Stock Purchase Agreement"), pursuant to
which Bion has agreed, as partial consideration for the purchase of certain
Centerpoint shares from OAM, to assign its interests under the Assignment
Agreement to OAM and OAM has agreed to accept such interests and to assume all
of Bion's obligations under the Assignment Agreement.
NOW, THEREFORE, in consideration of the premises and mutual covenants
and obligations hereafter set forth and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties,
intending to be legally bound, hereby agree as follows:
Section 1. Assignment, Assumption and Further Assurances. Bion hereby
assigns, conveys, transfers and sets over unto OAM, all of the rights of Bion
under the Assignment Agreement, including, without limitation, Bion's Assigned
Interest, and OAM hereby accepts such assignment from Bion and assumes all of
the obligations of Bion under the Assignment Agreement, including, without
limitation, Bion's obligations to pay its Pro Rata Share of the Expenses
pursuant to the Assignment Agreement. OAM agrees Bion is deemed to have paid
in full all of its Pro Rata Share of the Expenses incurred from the time of
Bion's receipt of the Assigned Interest from Centerpoint, that no Expenses
were incurred during the brief period of time that Bion owned the Assigned
Interest, and that Bion has no knowledge whatsoever of the substance, validity
or merit of the claims assigned hereby and Bion makes no warranty or other
representation of any kind in relation thereto. OAM agrees that it will
administer any litigation related to, settlement of, or other resolution of
the Action and the Assigned Interest, to the best of its ability, on its own
behalf and on behalf of Centerpoint as Centerpoint's authorized agent. OAM
agrees that its relationship with Centerpoint in connection with such
administration is that of a fiduciary to Centerpoint. OAM further agrees with
Centerpoint that (i) it will not settle, compromise or abandon the Action
without the consent of Centerpoint, which consent shall not be unreasonably
withheld or delayed, (ii) that it will consult with Centerpoint prior to
making any material change in its strategy in the litigation, and (iii) that
if it determines that it wants to abandon the Action, that OAM will assign the
Assigned Interest to Centerpoint for a consideration of $1, and that
Centerpoint shall have the right to continue to pursue the action at its own
cost and expense and solely for its own benefit.
Section 2. Fees and Expenses; Allocation of Award.
(1) OAM and Centerpoint shall each pay its respective pro rata share of
the direct costs and expenses associated with, or incurred in connection with,
the administration of the Action (such costs and expenses, the "Expenses").
Bion shall not be responsible for the payment of any Expenses. The procedure
for the payment of expenses by Centerpoint shall be as follows: each month
OAM shall provide Centerpoint with a reasonably itemized statement of the
Expenses actually incurred by OAM and paid to non-affiliated parties in
connection with the administration of the action, along with adequate proof of
payment. Centerpoint shall reimburse OAM for its Pro Rata Share of all such
Expenses reasonably incurred by OAM within 25 days of Centerpoint's receipt of
such itemized statement and proof of payment; provided, however, that
Centerpoint shall not be required to reimburse OAM for any Expenses until such
time as Centerpoint's Pro Rata Share exceeds a minimum "basket" amount of
$5,000. In the event that Centerpoint does not fully reimburse OAM for its
Pro Rata Share of reasonable Expenses in excess of the $5,000 basket amount as
set forth in the itemized statement within 25 days of Centerpoint's receipt of
such statement, Centerpoint shall thereupon forfeit its interest in the action
and proof of payment.
(2) If at any time after the date hereof, Bion receives any payment in
respect of, or in connection with, the Action, whether in the form of cash,
securities, instruments and/or other property or otherwise in connection with
any of the foregoing, or otherwise with respect to the Assigned Interest
assigned to OAM pursuant to this Agreement (an "Assigned Distribution"), Bion
shall be deemed to have received such distribution in a fiduciary capacity and
as trustee for OAM, and Bion shall with respect to any such Assigned
Distribution (i) accept and hold it for the account and sole benefit of OAM,
(ii) have no equitable or beneficial interest in it, and (iii) deliver it
promptly to OAM in the same form received and, when necessary or appropriate,
with Bion's endorsement (without recourse, representation, or warranty),
except to the extent prohibited under any applicable law, rule, or order.
(3) If any Assigned Distribution includes securities or other non-cash
property of any kind, Bion shall, to the extent permissible by law, endorse
(without recourse), assign, convey or otherwise cause to be registered in or
transferred to OAM's name, or such name as OAM may direct (at OAM's sole
expense) in writing, and deliver such securities or other non-cash property to
OAM as soon as practicable. Pending such transfer, Bion shall hold the same
as agent for OAM and Bion shall have no legal, equitable, or beneficial
interest in any such Assigned Distribution.
(4) If Bion receives any Assigned Distribution which it is required to
remit to OAM, OAM will furnish to Bion such forms, certifications, statements,
and other documents as Bion may reasonably request in writing to evidence
OAM's exemption from the withholding of any tax imposed by the United States
of America or any other jurisdiction, whether domestic or foreign, or to
enable Bion to comply with any applicable laws or regulations relating
thereto, and Bion may refrain from remitting such Assigned Distribution until
such forms, certifications, statements, and other documents have been so
furnished.
(5) If any Assigned Distribution received by Bion and transferred to OAM
pursuant to this Agreement has been made to Bion wrongfully or in error, and
is required to be returned or disgorged by Bion, Bion shall promptly return
such Assigned Distribution to OAM.
(6) If at any time after the date hereof, OAM receives any payment in
respect of, or in connection with, the Action (whether from Bion or from any
third party), whether in the form of cash, securities, instruments and/or
other property or otherwise with respect to the 35% interest in the Action
that is retained by Centerpoint (a "Centerpoint Distribution"), OAM shall be
deemed to have received such distribution in a fiduciary capacity and as
trustee for Centerpoint, and OAM shall with respect to any such Centerpoint
Distribution (i) accept and hold it for the account and sole benefit of
Centerpoint, (ii) have no equitable or beneficial interest in it, and (iii)
deliver it promptly to Centerpoint in the same form received (after deduction
of any Pro Rata Share of Expenses due and payable by Centerpoint) and, when
necessary or appropriate, with OAM's endorsement (without recourse,
representation, or warranty), except to the extent prohibited under any
applicable law, rule, or order.
(7) If any Centerpoint Distribution includes securities or other
non-cash property of any kind, OAM shall, to the extent permissible by law,
endorse (without recourse), assign, ▇▇▇▇▇ or otherwise cause to be registered
in or transferred to Centerpoint's name, or such name as Centerpoint may
direct (at Centerpoint's sole expense) in writing, and deliver such securities
or other non-cash property to Centerpoint as soon as practicable. Pending
such transfer, OAM shall hold the same as agent for Centerpoint and OAM shall
have no legal, equitable, or beneficial interest in any such Centerpoint
Distribution.
(8) If any Centerpoint Distribution received by OAM has been made to OAM
wrongfully or in error, and is required to be returned or disgorged by OAM,
OAM shall promptly return such Centerpoint Distribution to Centerpoint.
Section 3. Further Assurances. Each of Bion and OAM hereby covenants
and agrees that such party will do, execute, acknowledge and deliver all such
further acts, deeds, conveyances, assignments, affidavits, notices, transfers
and assurances as the other party shall from time to time reasonably request
in furtherance of and for the better assuring, assigning, conveying,
transferring and setting over to OAM Bion's rights under the Assignment
Agreement, or for otherwise carrying out the intention or facilitating the
performance of the terms of this Agreement.
Section 4. Miscellaneous.
(1) Incorporation by Reference. The Parties hereby agree that the terms
and provisions of Sections 6.1, 6.2, 6.4, 6.5, 6.7, and 6.8 through 6.16,
inclusive, of the Stock Purchase Agreement shall be incorporated herein as if
set forth in full.
(2) Survival of Representations and Warranties. All representations,
warranties, indemnities and agreements of the Parties as set forth in this
Agreement shall survive the Closing.
(3) Third Party Beneficiary. The parties hereto hereby agree that
Centerpoint and its successors and assigns shall be a third party beneficiary
under this Agreement.
[ REMAINDER OF PAGE INTENTIONALLY LEFT BLANK ]
IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed and delivered by their duly authorized officers as of the date first
above written.
BION ENVIRONMENTAL TECHNOLOGIES, INC.
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: CEO
OAM S.p.A.
By: ▇▇▇▇ ▇▇▇▇▇▇
Name:
Title:
EXHIBIT H
CENTERPOINT CORPORATION
▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
January 15, 2002
Board of Directors of OAM, S.p.A.
▇▇▇ ▇▇▇▇▇ ▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇
Gentlemen:
Centerpoint Corporation hereby agrees to be bound by the provisions of
(a) Section 3 of that certain Assignment of Assignment of Claims Agreement
and (b) Section 2 of that certain Assignment of Assignment of Escrow
Agreement, both of which agreements are dated January 10, 2002 and are by and
between Bion Environmental Technologies, Inc. and OAM, S.p.A.
Very truly yours,
CENTERPOINT CORPORATION
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇▇, President
ASSIGNMENT OF ASSIGNMENT
OF CLAIMS AGREEMENT
AGREEMENT (this "Agreement"), made as of this 10th day of January, 2002
by and between Bion Environmental Technologies, Inc., a Colorado corporation
("Bion") and OAM S.p.A., an Italian corporation ("OAM" and together with Bion,
the "Parties").
WHEREAS, Bion has on this date acquired from Centerpoint Corporation, a
Delaware corporation ("Centerpoint"), pursuant to that certain Assignment of
Claims Agreement, dated the date hereof, between Bion and Centerpoint (the
"Assignment Agreement"), a 65% interest in and to certain claims Centerpoint
may have, as the plaintiff, against Banca di Intermediazione Mobiliare IMI
S.p.A., an Italian corporation, in connection with IMI's deduction of amounts
from the Aprilia sale proceeds that it believes are in excess of the fee due
IMI under the Engagement Letter, and all claims, including Centerpoint's right
to receive principal, interest, fees, expenses, damages, penalties and other
amounts in respect of, or in connection with, any of the foregoing, together
with voting and other rights and benefits arising from, under or relating to
any of the foregoing, including, without limitation, all of Centerpoint's
rights to receive cash, securities, instruments and/or other property or
distributions issued in connection with any of the foregoing (collectively,
"Bion's Assigned Interest"); and
WHEREAS, Bion and OAM are entering into that certain Stock Purchase
Agreement, dated the date hereof (the "Stock Purchase Agreement"), pursuant to
which Bion has agreed, as partial consideration for the purchase of certain
Centerpoint shares from OAM, to assign its interests under the Assignment
Agreement to OAM and OAM has agreed to accept such interests and to assume all
of Bion's obligations under the Assignment Agreement.
NOW, THEREFORE, in consideration of the premises and mutual covenants
and obligations hereafter set forth and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties,
intending to be legally bound, hereby agree as follows:
Section 1. Assignment, Assumption and Further Assurances. Bion hereby
assigns, conveys, transfers and sets over unto OAM, all of the rights of Bion
under the Assignment Agreement, including, without limitation, Bion's Assigned
Interest, and OAM hereby accepts such assignment from Bion and assumes all of
the obligations of Bion under the Assignment Agreement, including, without
limitation, Bion's obligations to pay its Pro Rata Share of the Expenses
pursuant to the Assignment Agreement. OAM agrees Bion is deemed to have paid
in full all of its Pro Rata Share of the Expenses incurred from the time of
Bion's receipt of the Assigned Interest from Centerpoint, that no Expenses
were incurred during the brief period of time that Bion owned the Assigned
Interest, and that Bion has no knowledge whatsoever of the substance, validity
or merit of the claims assigned hereby and Bion makes no warranty or other
representation of any kind in relation thereto. OAM agrees that it will
administer any litigation related to, settlement of, or other resolution of
the Action and the Assigned Interest, to the best of its ability, on its own
behalf and on behalf of Centerpoint as Centerpoint's authorized agent.
Section 2. OAM agrees that its relationship with Centerpoint in
connection with such administration is that of a fiduciary to Centerpoint. OAM
further agrees with Centerpoint that (i) it will not settle, compromise or
abandon the Action without the consent of Centerpoint, which consent shall not
be unreasonably withheld or delayed, (ii) that it will consult with
Centerpoint prior to making any material change in its strategy in the
litigation, and (iii) that if it determines that it wants to abandon the
Action, that OAM will assign the Assigned Interest to Centerpoint for a
consideration of $1, and that Centerpoint shall have the right to continue to
pursue the action at its own cost and expense and solely for its own benefit.
Section 3. Fees and Expenses; Allocation of Award.
(1) OAM and Centerpoint shall each pay its respective pro rata share of
the direct costs and expenses associated with, or incurred in connection with,
the administration of the Action (such costs and expenses, the "Expenses").
Bion shall not be responsible for the payment of any Expenses. The procedure
for the payment of expenses by Centerpoint shall be as follows: each month
OAM shall provide Centerpoint with a reasonably itemized statement of the
Expenses actually incurred by OAM and paid to non-affiliated parties in
connection with the administration of the action, along with adequate proof of
payment. Centerpoint shall reimburse OAM for all such Expenses reasonably
incurred by OAM within 25 days of Centerpoint's receipt of such itemized
statement and proof of payment; provided, however, that Centerpoint shall not
be required to reimburse OAM for any Expenses until such time as
Centerpoint's Pro Rata Share exceeds a minimum "basket" amount of $5,000. In
the event that Centerpoint does not fully reimburse OAM for its reasonable
Expenses in excess of the $5,000 basket amount as set forth in the itemized
statement within 25 days of Centerpoint's receipt of such statement,
Centerpoint shall thereupon forfeit its interest in the action and proof of
payment.
(2) If at any time after the date hereof, Bion receives any payment in
respect of, or in connection with, the Action, whether in the form of cash,
securities, instruments and/or other property or otherwise in connection with
any of the foregoing (an "Assigned Distribution"), Bion shall be deemed to
have received such distribution in a fiduciary capacity and as trustee for
OAM, and Bion shall with respect to any such Assigned Distribution (i) accept
and hold it for the account and sole benefit of OAM, (ii) have no equitable or
beneficial interest in it, and (iii) deliver it promptly to OAM in the same
form received and, when necessary or appropriate, with Bion's endorsement
(without recourse, representation, or warranty), except to the extent
prohibited under any applicable law, rule, or order.
(3) If any Assigned Distribution includes securities or other non-cash
property of any kind, Bion shall, to the extent permissible by law, endorse
(without recourse), assign, convey or otherwise cause to be registered in or
transferred to OAM's name, or such name as OAM may direct (at OAM's sole
expense) in writing, and deliver such securities or other non-cash property to
OAM as soon as practicable. Pending such transfer, Bion shall hold the same
as agent for OAM and Bion shall have no legal, equitable, or beneficial
interest in any such Assigned Distribution.
(4) If Bion receives any Assigned Distribution which it is required to
remit to OAM, OAM will furnish to Bion such forms, certifications, statements,
and other documents as Bion may reasonably request in writing to evidence
OAM's exemption from the withholding of any tax imposed by the United States
of America or any other jurisdiction, whether domestic or foreign, or to
enable Bion to comply with any applicable laws or regulations relating
thereto, and Bion may refrain from remitting such Assigned Distribution until
such forms, certifications, statements, and other documents have been so
furnished.
(5) If any Assigned Distribution received by Bion and transferred to OAM
pursuant to this Agreement has been made to Bion wrongfully or in error, and
is required to be returned or disgorged by Bion, Bion shall promptly return
such Assigned Distribution to OAM.
(6) If at any time after the date hereof, OAM receives any payment in
respect of, or in connection with, the Action (whether from Bion or any third
party), whether in the form of cash, securities, instruments and/or other
property or otherwise with respect to the 35% interest in the Action that is
retained by Centerpoint (a "Centerpoint Distribution"), OAM shall be deemed to
have received such distribution in a fiduciary capacity and as trustee for
Centerpoint, and OAM shall with respect to any such Centerpoint Distribution
(i) accept and hold it for the account and sole benefit of Centerpoint, (ii)
have no equitable or beneficial interest in it, and (iii) deliver it promptly
to Centerpoint in the same form received (after deduction of any Pro Rata
Share of Expenses due and payable by Centerpoint) and, when necessary or
appropriate, with OAM's endorsement (without recourse, representation, or
warranty), except to the extent prohibited under any applicable law, rule, or
order.
(7) If any Centerpoint Distribution includes securities or other
non-cash property of any kind, OAM shall, to the extent permissible by law,
endorse (without recourse), assign, ▇▇▇▇▇ or otherwise cause to be registered
in or transferred to Centerpoint's name, or such name as Centerpoint may
direct (at Centerpoint's sole expense) in writing, and deliver such securities
or other non-cash property to Centerpoint as soon as practicable. Pending
such transfer, OAM shall hold the same as agent for Centerpoint and OAM shall
have no legal, equitable, or beneficial interest in any such Centerpoint
Distribution.
(8) If any Centerpoint Distribution received by OAM has been made to OAM
wrongfully or in error, and is required to be returned or disgorged by OAM,
OAM shall promptly return such Centerpoint Distribution to Centerpoint.
Section 4. Further Assurances. Each of Bion and OAM hereby covenants
and agrees that such party will do, execute, acknowledge and deliver all such
further acts, deeds, conveyances, assignments, affidavits, notices, transfers
and assurances as the other party shall from time to time reasonably request
in furtherance of and for the better assuring, assigning, conveying,
transferring and setting over to OAM Bion's rights under the Assignment
Agreement, or for otherwise carrying out the intention or facilitating the
performance of the terms of this Agreement.
Section 5. Miscellaneous.
(1) Incorporation by Reference. The Parties hereby agree that the terms
and provisions of Sections 6.1, 6.2, 6.4, 6.5, 6.7, and 6.8 through 6.16,
inclusive, of the Stock Purchase Agreement shall be incorporated herein as if
set forth in full.
(2) Survival of Representations and Warranties. All representations,
warranties, indemnities and agreements of the Parties as set forth in this
Agreement shall survive the Closing.
(3) Third Party Beneficiary. The parties hereto hereby agree that
Centerpoint and its successors and assigns shall be a third party beneficiary
under this Agreement.
[ REMAINDER OF PAGE INTENTIONALLY LEFT BLANK ]
IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed and delivered by their duly authorized officers as of the date first
above written.
BION ENVIRONMENTAL TECHNOLOGIES, INC.
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: CEO
OAM S.p.A.
By: /s/ ▇▇▇▇ ▇▇▇▇▇▇
Name:
Title: